<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis - Murray, A - 2020 | Cochrane Library</title> <meta content="Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis - Murray, A - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000543.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis - Murray, A - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000543.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000543.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis" name="citation_title"/> <meta content="Alistair Murray" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Tran M Nguyen" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Claire E Parker" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Brian G Feagan" name="citation_author"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="jmacdon1@uwo.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD000543.pub5" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000543.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000543.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000543.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal [*administration &amp; dosage, adverse effects]; Bias; Colitis, Ulcerative [*drug therapy]; Drug Administration Schedule; Induction Chemotherapy [methods]; Mesalamine [*administration &amp; dosage, adverse effects]; Patient Dropouts [statistics &amp; numerical data]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction; Sulfasalazine [*administration &amp; dosage, adverse effects]; Treatment Failure" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000543.pub5&amp;doi=10.1002/14651858.CD000543.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000543\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000543\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000543.pub5",title:"Oral 5\\u2010aminosalicylic acid for induction of remission in ulcerative colitis",firstPublishedDate:"Aug 12, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000543.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000543.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000543.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000543.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000543.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000543.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000543.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000543.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000543.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000543.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5782 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000543.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/appendices#CD000543-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/supinfo/CD000543StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/supinfo/CD000543StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#CD000543-cr-0004">Alistair Murray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#CD000543-cr-0005">Tran M Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#CD000543-cr-0006">Claire E Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#CD000543-cr-0007">Brian G Feagan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information#CD000543-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>John K MacDonald</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information/en#CD000543-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000543.pub5">https://doi.org/10.1002/14651858.CD000543.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000543-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000543-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000543-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000543-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000543-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000543-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000543-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000543-abs-0001" lang="en"> <section id="CD000543-sec-0001"> <h3 class="title" id="CD000543-sec-0001">Background</h3> <p>Oral 5‐aminosalicylic acid (5‐ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. It was previously found that 5‐ASA drugs in doses of at least 2 g/day were more effective than placebo but no more effective than SASP for inducing remission in ulcerative colitis (UC). This review is an update of a previously published Cochrane Review. </p> </section> <section id="CD000543-sec-0002"> <h3 class="title" id="CD000543-sec-0002">Objectives</h3> <p>To assess the efficacy, dose‐responsiveness and safety of oral 5‐ASA compared to placebo, SASP, or 5‐ASA comparators (i.e. other formulations of 5‐ASA) for induction of remission in active UC. A secondary objective was to compare the efficacy and safety of once‐daily dosing of oral 5‐ASA versus conventional dosing regimens (two or three times daily). </p> </section> <section id="CD000543-sec-0003"> <h3 class="title" id="CD000543-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase and the Cochrane Library on 11 June 2019. We also searched references, conference proceedings and study registers to identify additional studies. </p> </section> <section id="CD000543-sec-0004"> <h3 class="title" id="CD000543-sec-0004">Selection criteria</h3> <p>We considered randomized controlled trials (RCTs) including adults (aged 18 years or more) with active UC for inclusion. We included studies that compared oral 5‐ASA therapy with placebo, SASP, or other 5‐ASA formulations. We also included studies that compared once‐daily to conventional dosing as well as dose‐ranging studies. </p> </section> <section id="CD000543-sec-0005"> <h3 class="title" id="CD000543-sec-0005">Data collection and analysis</h3> <p>Outcomes include failure to induce global/clinical remission, global/clinical improvement, endoscopic remission, endoscopic improvement, adherence, adverse events (AEs), serious adverse events (SAEs), withdrawals due to AEs, and withdrawals or exclusions after entry. We analyzed five comparisons: 5‐ASA versus placebo, 5‐ASA versus sulfasalazine, once‐daily dosing versus conventional dosing, 5‐ASA (e.g. MMX mesalamine, Ipocol, Balsalazide, Pentasa, Olsalazine and 5‐ASA micropellets) versus comparator 5‐ASA (e.g. Asacol, Claversal, Salofalk), and 5‐ASA dose‐ranging. We calculated the risk ratio (RR) and 95% confidence interval (95% CI) for each outcome. We analyzed data on an intention‐to‐treat basis, and used GRADE to assess the overall certainty of the evidence. </p> </section> <section id="CD000543-sec-0006"> <h3 class="title" id="CD000543-sec-0006">Main results</h3> <p>We include 54 studies (9612 participants). We rated most studies at low risk of bias.</p> <p>Seventy‐one per cent (1107/1550) of 5‐ASA participants failed to enter clinical remission compared to 83% (695/837) of placebo participants (RR 0.86, 95% CI 0.82 to 0.89; 2387 participants, 11 studies; high‐certainty evidence). We also observed a dose‐response trend for 5‐ASA. There was no difference in clinical remission rates between 5‐ASA and SASP. Fifty‐four per cent (150/279) of 5‐ASA participants failed to enter remission compared to 58% (144/247) of SASP participants (RR 0.90, 95% CI 0.77 to 1.04; 526 participants, 8 studies; moderate‐certainty evidence). </p> <p>There was no difference in remission rates between once‐daily dosing and conventional dosing. Sixty per cent (533/881) of once‐daily participants failed to enter clinical remission compared to 61% (538/880) of conventionally‐dosed participants (RR 0.99, 95% CI 0.93 to 1.06; 1761 participants, 5 studies; high‐certainty evidence). Eight per cent (15/179) of participants dosed once daily failed to adhere to their medication regimen compared to 6% (11/179) of conventionally‐dosed participants (RR 1.36, 95% CI 0.64 to 2.86; 358 participants, 2 studies; low‐certainty evidence). </p> <p>There does not appear to be any difference in efficacy among the various 5‐ASA formulations. Fifty per cent (507/1022) of participants in the 5‐ASA group failed to enter remission compared to 52% (491/946) of participants in the 5‐ASA comparator group (RR 0.94, 95% CI 0.86 to 1.02; 1968 participants, 11 studies; moderate‐certainty evidence). </p> <p>There was no evidence of a difference in the incidence of adverse events and serious adverse events between 5‐ASA and placebo, once‐daily and conventionally‐dosed 5‐ASA, and 5‐ASA and comparator 5‐ASA formulation studies. Common adverse events included flatulence, abdominal pain, nausea, diarrhea, headache and worsening UC. SASP was not as well tolerated as 5‐ASA. Twenty‐nine per cent (118/411) of SASP participants experienced an AE compared to 15% (72/498) of 5‐ASA participants (RR 0.48, 95% CI 0.36 to 0.63; 909 participants, 12 studies; moderate‐certainty evidence). </p> </section> <section id="CD000543-sec-0007"> <h3 class="title" id="CD000543-sec-0007">Authors' conclusions</h3> <p>There is high‐certainty evidence that 5‐ASA is superior to placebo, and moderate‐certainty evidence that 5‐ASA is not more effective than SASP. Considering relative costs, a clinical advantage to using oral 5‐ASA in place of SASP appears unlikely. High‐certainty evidence suggests 5‐ASA dosed once daily appears to be as efficacious as conventionally‐dosed 5‐ASA. There may be little or no difference in efficacy or safety among the various 5‐ASA formulations. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000543-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000543-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000543-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000543-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000543-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000543-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000543-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000543-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000543-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000543-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000543-abs-0002" lang="en"> <h3>Oral 5‐aminosalicylic acid for the treatment of active ulcerative colitis</h3> <p><b>What is ulcerative colitis?</b> </p> <p>Ulcerative colitis (UC) is a condition that causes inflammation of your large intestine (colon). Some of the symptoms associated with UC include diarrhea, abdominal pain, rectal pain, rectal bleeding, weight loss, fatigue and fever. </p> <p><b>What is 5‐aminosalicylic acid (5‐ASA)?</b> </p> <p>Sulfasalazine (SASP) has been used for treating UC for decades. SASP is made up of 5‐aminosalicylic acid (5‐ASA) linked to a sulfur molecule. Up to a third of people treated with SASP have reported side effects, which are thought to be related to the sulfur part of the molecule. Common side effects associated with SASP include nausea, indigestion, headache, vomiting and abdominal pain. 5‐ASA drugs were developed to avoid the side effects associated with SASP. 5‐ASA is commonly taken by mouth. </p> <p><b>What did the researchers investigate?</b> </p> <p>The researchers examined whether oral 5‐ASA helps to cause remission in people with UC. The researchers investigated whether oral 5‐ASA was better than placebo (a fake medication) or a different 5‐ASA formulation. </p> <p><b>Key results</b> </p> <p>This review includes 54 randomized trials with a total of 9612 people taking part. The review includes studies published up to June 2019. Oral 5‐ASA was found to be more effective than placebo (fake drug). Although oral 5‐ASA drugs are effective for treating active UC, they are no more effective than SASP therapy. People taking 5‐ASA are less likely to experience side effects than those taking SASP. Side effects associated with 5‐ASA are generally mild in nature, and common side effects include digestive tract symptoms (e.g. flatulence, abdominal pain, nausea, and diarrhea), headache and worsening UC. 5‐ASA compounds are more expensive than SASP, so SASP may be the preferred option where cost is an important factor. 5‐ASA given once daily appears to be as effective as 5‐ASA given in the usual way (two or three times daily). There do not appear to be any differences in effectiveness or safety among the various 5‐ASA formulations. </p> <p><b>Conclusions</b> </p> <p>High‐certainty evidence suggests that 5‐ASA is superior to placebo and that 5‐ASA once‐daily dose has the same effectiveness and safety as the conventional 5‐ASA dose. Moderate‐certainty evidence also suggests that 5‐ASA is not superior to SASP. Sticking to the medication does not appear to improve with once‐daily dosing compared to conventional dosing. Lastly, there may be little or no difference in effectiveness or safety among the various 5‐ASA formulations. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000543-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000543-sec-0101"></div> <h3 class="title" id="CD000543-sec-0102">Implications for practice</h3> <section id="CD000543-sec-0102"> <p>5‐ASA was superior to placebo and no more effective than SASP. Nonetheless, it is clear that the newer 5‐ASA preparations have yet to be proven to be more clinically beneficial than SASP for the treatment of UC. The decision to use 5‐ASA or SASP should consider tolerance to SASP. Oral 5‐ASA administered once daily is as effective and safe as conventional dosing (twice or three times daily) for induction therapy in mild to moderately‐active UC. There do not appear to be any differences in efficacy or safety between the various formulations of 5‐ASA. Among people with mildly‐active UC a dosage of 4 to 4.8 g/day does not appear to provide any additional benefit over a dosage of 2 to 2.4 g/day. Patients with severe symptoms and moderately‐active disease may benefit from an initial dosage of 4 to 4.8 g/day.<br/>When selecting among the various 5‐ASA formulations, physicians and patients should consider dose‐response data, adherence issues related to dose forms (size of dose form and total number of tablets or capsules per day) (<a href="./references#CD000543-bbs2-0121" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>). </p> </section> <h3 class="title" id="CD000543-sec-0103">Implications for research</h3> <section id="CD000543-sec-0103"> <p>Future trials comparing the efficacy of oral 5‐ASA with placebo or SASP do not appear to be justified. There is little evidence to suggest that there is a difference in efficacy between the oral 5‐ASA drugs.<br/><br/>Future trials should look at enhancing patient adherence to medication. Adherence to therapy is important for treatment success and may be an important predictor of relapse (<a href="./references#CD000543-bbs2-0102" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>; <a href="./references#CD000543-bbs2-0101" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>). </p> <p>Future trials could assess whether once‐daily dosing regimens improve adherence in the community. There is currently one ongoing study comparing 5‐ASA to placebo. One of the trials (<a href="./references#CD000543-bbs2-0076" title="NCT02522767. Mesalamine 4 g sachet for the induction of remission in active, mild to moderate ulcerative colitis (UC) (Ferring Pharmaceuticals). clinicaltrials.gov/show/NCT02522767 (first received 13 August 2015). ">NCT02522767</a>) assessed a 4 g extended‐release once‐daily dosing regimen, but did not assess medication adherence.<br/>Future trials may be necessary to identify people who will benefit from varying doses of MMX mesalamine or Salofalk. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000543-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000543-sec-0008"></div> <div class="table" id="CD000543-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral 5‐ASA versus placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral 5‐ASA versus placebo for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Oral 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce complete global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>830 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b><br/>(681 to 739) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/>(0.82 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2387<br/>(11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as a score of 0 points for stool frequency and rectal bleeding </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>651 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b><br/>(397 to 488) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> <br/>(0.61 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2256<br/>(14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as a decrease of 3 points from baseline in the overall modified UC‐DAI score </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> <p>Follow‐up: 6 ‐ 14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>639 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> </p> <p>(428 to 569)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> </p> <p>(0.67 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1154</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic improvement was defined as endoscopy/sigmoidoscopy score of ≤ 1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome is not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><br/>(413 to 520) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/>(0.85 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1218<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included headache, nausea, abdominal pain or cramps, nasopharyngitis or symptoms of upper respiratory infection, rash. anorexia or loss of appetite, flatulence or gas, gastrointestinal disorders and fever </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1,000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> <p>(4 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> </p> <p>(0.18 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>746</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included aggravation of UC, malaise, abdominal abscess, pancreatitis and an inguinal hernia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b><br/>(47 to 85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b><br/>(0.54 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2372<br/>(13 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal were not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio <b>UC:</b> ulcerative colitis; <b>UC‐DAI: ulcerative colitis ‐ disease activity index</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to heterogeneity I<sup>2</sup> = 47%.<br/><sup>c</sup>Downgrade one level due to heterogeneity I<sup>2</sup> = 42%.<br/><sup>d</sup>Downgraded two levels due to very sparse data (13 events).<br/><sup>e</sup>Downgraded one level due to sparse data (164 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000543-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral 5‐ASA versus SASP for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral 5‐ASA versus SASP for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Oral 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SASP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>583 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>525 per 1000</b><br/>(449 to 606) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> <br/>(0.77 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>526<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as the return to stool frequency (2 ‐ 3 stools or fewer a day) without the presence of blood </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b><br/>(355 to 472) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/>(0.76 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1053<br/>(14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as reduction in their clinical activity index</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported this outcome but meta‐analysis not performed as they used different measurement indices. Neither study showed significant differences in complete endoscopic remission between 5‐ASA and SASP </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>287 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b><br/>(103 to 181) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> <br/>(0.36 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>909<br/>(12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included nausea, headache, dyspepsia, vomiting, abdominal pain and rash </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> <p>(11 to 246)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(0.28 to 6.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included erythematous rash, venous thrombosis, carcinoma, acute pancreatitis, rheumatoid arthritis and erythema nodosum </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b><br/>(31 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.40</b> <br/>(0.24 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included nausea, headaches and rashes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to sparse data (294 events).<br/><sup>c</sup>Downgraded one level due to sparse data (190 events).<br/><sup>d</sup>Downgraded two levels due to very sparse data (5 events).<br/><sup>e</sup>Downgraded one level due to sparse data (54 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000543-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Once daily dosing versus conventional dosing for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Once‐daily dosing versus conventional dosing for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Once‐daily dosing </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Conventional dosing</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Once daily dosing</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>611 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>605 per 1000</b><br/>(569 to 648) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.93 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1761<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as UC‐DAI score of ≤ 1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/>(180 to 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/>(0.49 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as decrease of ≤ 3 points from baseline in the total modified UC‐DAI score </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>892 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>910 per 1000</b><br/>(180 to 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.98 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>817<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic remission was defined as Mayo Clinic Endoscopic Subscale subscore of 0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b><br/>(39 to 176) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> <br/>(0.64 to 2.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence to medication regimen was defined as compliance with taking medications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>318 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b><br/>(283 to 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.89 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1586<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included flatulence, abdominal pain, nausea, diarrhea, nasopharyngitis, dyspepsia, headache and worsening of ulcerative colitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> <p>(12 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b> </p> <p>(0.68 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1586</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included pancreatitis, hepatitis, polyuria, chromaturia, upper respiratory tract infection and measles </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b><br/>(18 to 49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.54 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1757<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal were not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio; <b>UC:</b> ulcerative colitis; <b>UC‐DAI: ulcerative colitis ‐ disease activity index</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to sparse data (153 events).<br/><sup>c</sup>Downgraded two levels due to very sparse data (26 events).<br/><sup>d</sup>Downgraded one level due to sparse data (271 events).<br/><sup>e</sup>Downgraded two levels due to very sparse data (33 events).<br/><sup>f</sup>Downgraded two levels due to very sparse data (9 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000543-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral 5‐ASA versus comparator 5‐ASA for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Oral 5‐ASA versus comparator 5‐ASA for induction of remission in ulcerative colitis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Oral 5‐ASA (MMX mesalamine, Ipocol, Balsalazide, Pentasa, Olsalazine and 5‐ASA micropellets) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>519 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>488 per 1000</b><br/>(446 to 529) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.86 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1968</p> <p>(11 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as CAI ≤ 4 for patient functional assessment ratings or normal bowel movements and absence of rectal bleeding </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/>(267 to 350) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/>(0.77 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1647</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as improved CAI by ≤ 3 from baseline</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b><br/>(420 to 511) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/>(0.92 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1576</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included headache, abdominal pain, nausea, flatulence, diarrhea, nasopharyngitis, dyspepsia and vomiting </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1,000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p>(7 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.22 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>677</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included aggravation of UC and a colonic polyp</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(22 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.57 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1489</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal include abdominal pain, rashes and cephalea</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CAI:</b> clinical activity index; <b>CI:</b> Confidence interval; <b>RR:</b> risk ratio; <b>UC:</b> ulcerative colitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to high risk of bias in two studies in the pooled analysis (both due to lack of blinding).<br/><sup>c</sup>Downgraded one level due to high risk of bias in one study in the pooled analysis (lack of blinding).<br/><sup>d</sup> Downgraded one level due to high risk of bias in one study in the pooled analysis (lack of blinding).<br/><sup>e</sup>Downgraded two levels due to very sparse data (12 events).<br/><sup>f</sup>Downgraded one level due to sparse data (57 events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000543-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000543-sec-0009"></div> <section id="CD000543-sec-0010"> <h3 class="title" id="CD000543-sec-0010">Description of the condition</h3> <p>Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by the inflammation of the colon. The pathogenesis of UC is still unknown, but there are genetic and environmental factors that have been correlated with the increased risk. Common symptoms for UC include abdominal pain, diarrhea, rectal pain, rectal bleeding, weight loss, fatigue and fever (<a href="./references#CD000543-bbs2-0083" title="ConradK , RoggenbuckD , LaassMW . Diagnosis and classification of ulcerative colitis. Autoimmunity Reviews2014;13(4-5):463-6.">Conrad 2014</a>; <a href="./references#CD000543-bbs2-0090" title="FeuersteinJD , CheifetzAS . Ulcerative colitis. Mayo Clinic Proceedings2014;89(11):1553-63.">Feuerstein 2014</a>). Approximately 6% to 47% of patients experience extra‐intestinal manifestations affecting the eyes, joints, liver and skin. Some of these extra‐intestinal manifestations include arthritis, uveitis, oral ulcers, and primary sclerosing cholangitis (<a href="./references#CD000543-bbs2-0120" title="RothfussKS , StangeEF , HerrlingerKR . Extraintestinal manifestations and complications in inflammatory bowel diseases. World Journal of Gastroenterology2006;12(30):4819-31.">Rothfuss 2006</a>). UC is more common in the industrialized world, especially in North America and Western Europe. The overall worldwide incidence is 1.2 to 20.3 cases per 100,000 persons a year, with a prevalence of 7.6 to 245 cases per 100,000 a year (<a href="./references#CD000543-bbs2-0084" title="DaneseS , FiocchiC . Ulcerative colitis. New England Journal of Medicine2011;365(18):1713-25.">Danese 2011</a>; <a href="./references#CD000543-bbs2-0108" title="LoftusEJ . Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology2004;126(6):1504-17.">Loftus 2004</a>). In North America, the prevalence of UC ranges from 120 to 250 cases per 100,000 people and the incidence ranges from 8 to 20 cases per 100,000 people (<a href="./references#CD000543-bbs2-0108" title="LoftusEJ . Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology2004;126(6):1504-17.">Loftus 2004</a>). </p> <p>UC occurs equally in both men and women and the diagnosis of UC may occur at any age; the disease has two peaks in incidence, at 15 to 30 years and at 50 to 70 years (<a href="./references#CD000543-bbs2-0115" title="OrdásI , EckmannL , TalaminiM , BaumgartDC , SandbornWJ . Ulcerative colitis. Lancet2012;380(9853):1606-19.">Ordás 2012</a>; <a href="./references#CD000543-bbs2-0117" title="PonderA , LongMD . A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clinical Epidemiology2013;5:237-47.">Ponder 2013</a>). </p> <p>Treatments for UC are based on the severity of the symptoms and may include biological therapies (Adalimumab, Infliximab, Vedolizumab, Golimumab, Ustekinumab), corticosteroids, azathioprine or 6‐mercaptopurine and 5‐aminosalicylates (5‐ASAs). For people with mild‐to‐moderate UC, 5‐ASAs and corticosteroids are the conventional treatment for induction of remission. This is followed by thiopurines, anti‐TNFs or adhesion molecule inhibitors for moderate‐to‐severe UC (<a href="./references#CD000543-bbs2-0090" title="FeuersteinJD , CheifetzAS . Ulcerative colitis. Mayo Clinic Proceedings2014;89(11):1553-63.">Feuerstein 2014</a>). </p> </section> <section id="CD000543-sec-0011"> <h3 class="title" id="CD000543-sec-0011">Description of the intervention</h3> <p>The successful management of UC was greatly facilitated after the introduction of sulfasalazine (SASP) by Svartz (<a href="./references#CD000543-bbs2-0131" title="SvartzN . Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavia1942;110:557-90.">Svartz 1942</a>). SASP is composed of 5‐ASA linked to sulfapyridine by a diazo bond. This bond is readily cleaved by bacterial azoreductases in the colon (<a href="./references#CD000543-bbs2-0116" title="PeppercornMA , GoldmanP . The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. Journal of Pharmacology and Experimental Therapeutics1972;181(3):555-62.">Peppercorn 1972</a>), to yield the two components. Of these, 5‐ASA has been found to be the therapeutically active component, while sulfapyridine, which is primarily absorbed into systemic circulation, is assumed to function solely as a carrier molecule (<a href="./references#CD000543-bbs2-0079" title="Azad KhanAK , PirisJ , TrueloveSC . An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet1977;2(8044):892-5.">Azad Khan 1977</a>; <a href="./references#CD000543-bbs2-0106" title="KlotzU , MaierK , FischerC , HeinkelK . Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine1980;303(26):1499-502.">Klotz 1980</a>; <a href="./references#CD000543-bbs2-0134" title="Van HeesPA , BakkerJH , TongerenJH . Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut1980;21(7):632-5.">Van Hees 1980</a>). </p> </section> <section id="CD000543-sec-0012"> <h3 class="title" id="CD000543-sec-0012">How the intervention might work</h3> <p>Administration of unbound or uncoated 5‐ASA revealed that it was readily absorbed in the upper jejunum and was unable to reach the colon in therapeutic concentrations (<a href="./references#CD000543-bbs2-0112" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28(2):196-200.">Myers 1987</a>; <a href="./references#CD000543-bbs2-0114" title="NielsenOH , BondesenS . Kinetics of 5-aminosalicylic acid after jejunal instillation in man. British Journal of Clinical Pharmacology1983;16(6):738-40.">Nielsen 1983</a>; <a href="./references#CD000543-bbs2-0125" title="SchroederH , CampbellDE . Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics1972;13(4):539-51.">Schroeder 1972</a>). Ingested SASP largely resists such premature absorption and thus is able to serve as a delivery system that transports the 5‐ASA to the affected regions of the lower intestinal tract (<a href="./references#CD000543-bbs2-0125" title="SchroederH , CampbellDE . Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics1972;13(4):539-51.">Schroeder 1972</a>). While corticosteroid therapy is more effective for the treatment of severe UC (<a href="./references#CD000543-bbs2-0132" title="TrueloveSC , WittsLJ . Cortisone in ulcerative colitis: Final report on a therapeutic trial. British Medical Journal1955;2(4947):1041-8.">Truelove 1955</a>; <a href="./references#CD000543-bbs2-0133" title="TrueloveSC , WittsLJ . Cortisone and corticotrophin in ulcerative colitis. British Medical Journal1959;1(5119):387-94.">Truelove 1959</a>) the use of SASP in maintaining remission has been well established (<a href="./references#CD000543-bbs2-0111" title="MisiewitzJJ , Lennard-JonesJE , ConnellAM , BaronJH , JonesFA . Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet1965;1:185-8.">Misiewitz 1965</a>; <a href="./references#CD000543-bbs2-0130" title="SutherlandLR , MacDonaldJK . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD000544. [DOI: 10.1002/14651858.CD000544.pub2]">Sutherland 2006a</a>). </p> <p>Despite its benefits, up to 30% of patients receiving SASP have reported adverse events (AEs) (<a href="./references#CD000543-bbs2-0113" title="NielsenOH . Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology1982;17(3):389-93.">Nielsen 1982</a>). It was concluded that many were due to the sulfapyridine moiety, especially those effects found to be dose‐dependent (<a href="./references#CD000543-bbs2-0085" title="DasKM , EastwoodMA , McManusJP , SircusW . Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New England Journal of Medicine1973;289(10):491-5.">Das 1973</a>; <a href="./references#CD000543-bbs2-0112" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28(2):196-200.">Myers 1987</a>). This discovery spawned more than a decade of research aimed at finding alternative 5‐ASA delivery systems. </p> <p>Asacol<sup>®</sup> (Proctor and Gamble) consists of a pellet of 5‐ASA destined for release in the terminal ileum or colon due to a coating known as Eudragit‐S, a resin that dissolves at a pH greater than 7 (<a href="./references#CD000543-bbs2-0086" title="DewMJ , HughesPJ , LeeMG , EvansBK , RhodesJ . An oral preparation to release drugs in the human colon. British Journal of Clinical Pharmacology1982;14(3):405-8.">Dew 1982</a>). Claversal<sup>®</sup>/Mesasal<sup>®</sup> (Smith, Kline and French), Salofalk<sup>®</sup> (Axcan Pharma, Falk Foundation), and Rowasa<sup>®</sup> (Reid‐Rowell) are similar delayed‐release preparations of 5‐ASA pellets coated with Eudragit L, a resin that dissolves at a pH greater than 6 (the approximate pH of the ileum/colon) (<a href="./references#CD000543-bbs2-0095" title="HardyJG , HealeyJN , ReynoldsJR . Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Alimentary Pharmacology &amp; Therapeutics1987;1(4):273-80.">Hardy 1987</a>; <a href="./references#CD000543-bbs2-0112" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28(2):196-200.">Myers 1987</a>). Pentasa<sup>®</sup> (Marion‐Merrell‐Dow) is a microsphere formulation that consists of 5‐ASA microgranules enclosed within a semi‐permeable membrane of ethylcellulose. It is designed for controlled release that begins in the duodenum and continues into the affected regions of the lower bowel (<a href="./references#CD000543-bbs2-0119" title="RasmussenSN , BondesenS , HvidbergEF , HansenSH , BinderV , HalskouS , et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology1982;83(5):1062-70.">Rasmussen 1982</a>). Olsalazine/Dipentum<sup>®</sup> (Pharmacia &amp; Upjohn) consists of two 5‐ASA molecules linked by a diazo bond (<a href="./references#CD000543-bbs2-0128" title="Staerk LaursenL , StokholmM , BukhaveK , Rask-MadsenJ , LauritsenK . Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut1990;31(11):1271-6.">Staerk Laursen 1990</a>; <a href="./references#CD000543-bbs2-0135" title="WilloughbyCP , AronsonJK , AgbackH , BodinNO , TrueloveSC . Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut1982;23(12):1081-7.">Willoughby 1982</a>). Other formulations, such as benzalazine, Balsalazide/Colazide<sup>®</sup> (Astra Zeneca), and Balsalazide disodium/Colazal<sup>®</sup> (Salix Pharmaceuticals) are composed of 5‐ASA molecules azo‐bonded to various benzoic acid derivatives (<a href="./references#CD000543-bbs2-0082" title="ChanRP , PopeDJ , GilbertAP , SacraPJ , BaronJH , Lennard-JonesJE . Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive Diseases and Sciences1983;28(7):609-15.">Chan 1983</a>; <a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>). Like SASP, these compounds are poorly absorbed in the upper digestive tract </p> <p>but are readily metabolized by the intestinal flora in the lower bowel. MMX mesalamine (Lialdaa<sup>®</sup> or Mezavant<sup>®</sup>) uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). The newer 5‐ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits; however, they are more expensive and have also been shown to cause adverse effects in some people (<a href="./references#CD000543-bbs2-0118" title="RaoSS , CannPA , HoldsworthCD . Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scandinavian Journal of Gastroenterology1987;22(3):332-6.">Rao 1987</a>). The efficacy and safety of 5‐ASA preparations have been evaluated in numerous clinical trials that have often lacked sufficient statistical power to arrive at definitive conclusions. </p> <p>Many patients are non‐adherent to conventional multi‐dose treatment regimens (two or three times daily), which may result in reduced efficacy and can lead to an increased risk of relapse in patients with quiescent disease (<a href="./references#CD000543-bbs2-0101" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000543-bbs2-0102" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>), a poorer long‐term prognosis (<a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>) and increased healthcare costs (<a href="./references#CD000543-bbs2-0080" title="BeaulieuDB , SchwartzDA . Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes. Medscape CME Gastroenterology 2009. Available from www.medscape.org/viewarticle/713895.">Beaulieu 2009</a>; <a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>). Poor adherence may be particularly problematic in quiescent disease (<a href="./references#CD000543-bbs2-0101" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000543-bbs2-0102" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>), since patients lack continuing symptoms that incentivize them to take medication. Although multiple factors have been shown to influence medication adherence in people with UC, it is commonly believed that a high pill burden and multi‐dose regimens are major determinants (<a href="./references#CD000543-bbs2-0088" title="EdigerJP , WalkerJR , GraffL , LixL , ClaraI , RawsthorneP , et al. Predictors of medication adherence in inflammatory bowel disease. American Journal of Gastroenterology2007;102(7):1417-26.">Ediger 2007</a>; <a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>). Other factors affecting adherence in people with UC include disease extent and duration, medication costs, fear of side effects, individual psychosocial characteristics and the patient‐physician relationship (<a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>). Mesalamine formulations that involve once‐daily dosing may improve adherence and outcomes. </p> <p>Previous systematic reviews (<a href="./references#CD000543-bbs2-0136" title="FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub3]">Feagan 2012</a>; <a href="./references#CD000543-bbs2-0137" title="SutherlandLR , MayGR , ShafferEA . Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine1993;118:540-9.">Sutherland 1993</a>; <a href="./references#CD000543-bbs2-0138" title="SutherlandLR , RothDE , BeckPL . Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases1997;3:65-78.">Sutherland 1997</a>; <a href="./references#CD000543-bbs2-0139" title="SutherlandLR , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub2]">Sutherland 2006b</a>) found that oral 5‐ASA, in doses of at least 2 g/day, was more effective than placebo, but no more effective than SASP for induction of remission in UC. We proceeded with this updated review in order to include more recent studies as well as to evaluate the efficacy, dose‐responsiveness (including dose‐ranging studies of various 5‐ASA formulations), and safety of oral 5‐ASA preparations compared to placebo or SASP. We also aimed to investigate any differences in efficacy and safety between various formulations of oral 5‐ASA. </p> </section> <section id="CD000543-sec-0013"> <h3 class="title" id="CD000543-sec-0013">Why it is important to do this review</h3> <p>We conducted this review to assess the evidence supporting the use of oral 5‐ASA for the treatment of UC. A secondary objective of this systematic review was to investigate the efficacy and safety of once‐daily dosing of mesalamine compared to conventional dosing for the treatment of active UC. This systematic review is an update of a previously‐published Cochrane Review (<a href="./references#CD000543-bbs2-0136" title="FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub3]">Feagan 2012</a>; <a href="./references#CD000543-bbs2-0137" title="SutherlandLR , MayGR , ShafferEA . Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine1993;118:540-9.">Sutherland 1993</a>; <a href="./references#CD000543-bbs2-0138" title="SutherlandLR , RothDE , BeckPL . Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases1997;3:65-78.">Sutherland 1997</a>; <a href="./references#CD000543-bbs2-0139" title="SutherlandLR , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub2]">Sutherland 2006b</a>; <a href="./references#CD000543-bbs2-0140" title="WangY , ParkerCE , BhanjiT , FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub4]">Wang 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000543-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000543-sec-0014"></div> <p>To assess the efficacy, dose‐responsiveness, and safety of oral 5‐aminosalicylic acid (5‐ASA) compared to placebo, sulfasalazine (SASP), or 5‐ASA comparators (i.e. other formulations of 5‐ASA) for induction of remission in active UC. A secondary objective was to compare the efficacy and safety of once‐daily dosing of oral 5‐ASA with conventional dosing regimens (two or three times daily) . </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000543-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000543-sec-0015"></div> <section id="CD000543-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000543-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered prospective, randomized controlled clinical trials of parallel design for inclusion, with a minimum treatment duration of four weeks. </p> </section> <section id="CD000543-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adult participants (aged 18 years or more) with active mild‐to‐moderate UC as defined by <a href="./references#CD000543-bbs2-0132" title="TrueloveSC , WittsLJ . Cortisone in ulcerative colitis: Final report on a therapeutic trial. British Medical Journal1955;2(4947):1041-8.">Truelove 1955</a>. </p> </section> <section id="CD000543-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Studies of oral 5‐ASA therapy for treatment of participants with active UC compared with placebo, SASP or other formulations of 5‐ASA. We also considered studies that compared once‐daily 5‐ASA treatment with conventional dosing of 5‐ASA (two or three times daily), and 5‐ASA dose‐ranging studies for inclusion. </p> </section> <section id="CD000543-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcome measures included endoscopic, global or clinical measures of improvement or complete remission, as defined by the authors of each study. </p> <section id="CD000543-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome was the proportion of participants who failed to enter complete global or clinical remission, as defined by the authors of each study and expressed as a percentage of total participants randomized (intention‐to‐treat (ITT) analysis). </p> </section> <section id="CD000543-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included:</p> <p> <ol id="CD000543-list-0001"> <li> <p>proportion of participants who failed to improve clinically;</p> </li> <li> <p>proportion of participants who failed to enter endoscopic remission;</p> </li> <li> <p>proportion of participants who failed to improve endoscopically;</p> </li> <li> <p>proportion of participants who failed to adhere to their medication regimen;</p> </li> <li> <p>proportion of participants who experienced at least one adverse event (AE);</p> </li> <li> <p>proportion of participants who experienced at least one serious adverse event (SAE);</p> </li> <li> <p>proportion of participants who withdrew due to AEs; and</p> </li> <li> <p>proportion of participants excluded or withdrawn after entry.</p> </li> </ol> </p> </section> </section> </section> <section id="CD000543-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000543-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception to 11 June 2019:</p> <p> <ol id="CD000543-list-0002"> <li> <p>The Cochrane IBD group Specialized Register;</p> </li> <li> <p>MEDLINE (Ovid);</p> </li> <li> <p>Embase (Ovid):</p> </li> <li> <p>The Cochrane Library; and</p> </li> <li> <p><a href="http://Clinicaltrials.gov" target="_blank">Clinicaltrials.gov</a>. </p> </li> </ol> </p> <p>We applied no language or document type restrictions. The search strategies are listed in <a href="./appendices#CD000543-sec-0107">Appendix 1</a>. </p> </section> <section id="CD000543-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched review articles and conference proceedings to identify additional studies. </p> </section> </section> <section id="CD000543-sec-0026"> <h3 class="title" id="CD000543-sec-0026">Data collection and analysis</h3> <section id="CD000543-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AM and TN) independently selected relevant studies for analysis on the basis of the inclusion criteria described above. When necessary, we contacted the original investigators to clarify points about trial methodology. Disagreement between review authors were discussed and agreement was reached by consensus. </p> </section> <section id="CD000543-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AM and TN) independently extracted data using a standard data extraction form. We recorded results on an ITT basis, regardless of whether or not the original authors had done so. We settled any discrepancies between review authors by consensus. We extracted the following data: </p> <p> <ol id="CD000543-list-0003"> <li> <p>Baseline characteristics of the participants (age, sex, disease severity, disease duration) </p> </li> <li> <p>Intervention type (dose, mode of administration)</p> </li> <li> <p>Control type (placebo, no control, other intervention)</p> </li> <li> <p>Prespecified primary and secondary outcomes</p> </li> </ol> </p> </section> <section id="CD000543-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AM and TN) independently assessed the risks of bias in the included studies using the Cochrane 'Risk of bias' tool (<a href="./references#CD000543-bbs2-0098" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Factors assessed included: </p> <p> <ol id="CD000543-list-0004"> <li> <p>Random sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding;</p> </li> <li> <p>Incomplete outcome data;</p> </li> <li> <p>Selective outcome reporting; and</p> </li> <li> <p>Other potential sources of bias.</p> </li> </ol> </p> <p>Based on these criteria, studies were judged to have a low, high or unclear risk of bias for each category. Disagreements resolved by consensus. We contacted study authors when insufficient information was provided to determine risks of bias. </p> </section> <section id="CD000543-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). We pooled the results for each comparison group to determine the RR and 95% CI for each outcome resulting from 5‐ASA therapy relative to either placebo, SASP or 5‐ASA comparator, and for once‐daily 5‐ASA therapy relative to conventional dosing. We used a fixed‐effect model. We pooled studies for analysis if participants, outcomes and interventions were similar (determined by consensus among review authors). We pooled studies comparing 5‐ASA formulations for analysis if they compared equimolar doses of oral 5‐ASA. </p> </section> <section id="CD000543-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In trials consisting of multiple arms (i.e. different dose groups), we divided the placebo group across treatment groups. For trials with an odd number of participants, we divided the groups to ensure the group for the lower dose had the larger number of participants, to avoid overestimating the effects of the higher‐dose arm. For recurring events such as AEs and SAEs, we used the primary endpoint defined by the study. Lastly, we assessed the fixed intervals for follow‐up for outcomes that are measured at different time points. </p> </section> <section id="CD000543-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed missing dichotomous outcomes according to the ITT principle. Participants with missing data were assumed to be treatment failures. For continuous outcomes we used the number of participants who completed the trial and did not impute any missing variables. </p> </section> <section id="CD000543-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the presence of heterogeneity among studies using the Chi<sup>2</sup> test (with a P value of 0.10 regarded as statistically significant) and the I<sup>2</sup> statistic (<a href="./references#CD000543-bbs2-0097" title="HigginsJP , ThompsonSG , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). If we found statistically significant heterogeneity, we calculated the RR and 95% CI using a random‐effects model. We did not pool data for meta‐analysis if we identified a high degree of heterogeneity (e.g. I<sup>2</sup> &gt; 75%). </p> </section> <section id="CD000543-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We compared the outcomes listed in the protocol to the outcomes listed in the final study report. However, if we could not located the protocol we compared the outcomes listed in the Methods section to the outcomes in the Results section. If there were a sufficient number of studies included ( i.e. 10 or more ) in the pooled analyses, we planned to use a funnel plot to investigate a potential publication bias. </p> </section> <section id="CD000543-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We separated the trials into five comparison groups: 5‐ASA versus placebo; 5‐ASA versus sulfasalazine; once‐daily dosing versus conventional dosing; 5‐ASA versus comparator 5‐ASA; and 5‐ASA dose‐ranging. We pooled data from studies where the intervention, participant groups and outcomes were similar. The RR and 95% CI were pooled for dichotomous outcomes and the MD and corresponding 95% CI were pooled for continuous outcomes. We used the standardized mean difference (SMD) and a 95% CI when different scales were used to measure the same outcome (e.g. different quality‐of‐life instruments). </p> </section> <section id="CD000543-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We subgrouped once‐daily versus conventional‐dosing studies by formulation. We subgrouped the tables for 5‐ASA‐controlled trials by common 5‐ASA comparators (e.g. Asacol, Claversal, Salofalk and Pentasa). We subgrouped the tables for dose‐ranging studies by 5‐ASA formulation. Trials were also subgrouped according to the specific 5‐ASA preparation for those outcomes for which there were two or more studies that used a similar drug. </p> </section> <section id="CD000543-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses as appropriate, to investigate heterogeneity. We also conducted sensitivity analyses excluding studies with a high risk of bias. We conducted all statistical analyses using Cochrane Review Manager 5 software. </p> </section> <section id="CD000543-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach for rating the overall certainty of evidence for the primary outcomes and selected secondary outcomes of interest. Randomized trials start as high‐certainty evidence, but may be downgraded due to: (1) limitations in design and implementation (risk of bias), (2) indirectness of evidence, (3) inconsistency (unexplained heterogeneity), (4) imprecision (sparse data), and (5) reporting bias (publication bias). The overall certainty of evidence for each outcome is determined after considering each of these elements, and categorized as high certainty (i.e. further research is very unlikely to change our confidence in the estimate of effect); moderate certainty (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low certainty (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); and very low certainty (i.e. we are very uncertain about the estimate) (<a href="./references#CD000543-bbs2-0094" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>; <a href="./references#CD000543-bbs2-0126" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.training.cochrane.org/handbook.">Schünemann 2019</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000543-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000543-sec-0039"></div> <section id="CD000543-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD000543-sec-0041"> <h4 class="title">Results of the search</h4> <p>A literature search conducted on 11 June 2019 identified 3331 studies. We found 32 additional studies through searching of references. After duplicates were removed, 2300 reports remained for review of titles and abstracts. Two review authors (AM and TMN) independently reviewed the titles and abstracts of these studies and selected 115 reports of oral 5‐ASA for treatment of active UC for full‐text review (See <a href="#CD000543-fig-0001">Figure 1</a>). We excluded 22 reports of 21 of these studies (see <a href="./references#CD000543-sec-0115" title="">Characteristics of excluded studies</a>), leaving 92 reports of 54 included studies (<a href="./references#CD000543-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. In: Clinical Controversies in Inflammatory Bowel Disease. 1987:170. ">Andreoli 1987</a>; <a href="./references#CD000543-bbs2-0002" title="BresciG , CarraiM , VenturiniG , GambardellaL . Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity. International Journal of Tissue Reactions1990;12(4):243-6. ">Bresci 1990</a>; <a href="./references#CD000543-bbs2-0003" title="CaiJT , WuLF , DuQ , QianKD . Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion2001;21(10):593-5. ">Cai 2001</a>; <a href="./references#CD000543-bbs2-0004" title="D'HaensG , HommesD , EngelsL , BaertF , Van der WaaijL , ConnorP , et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacology and Therapeutics2006;24(7):1087-97. ">D'Haens 2006</a>; <a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>; <a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>; <a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>;<a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0012" title="ForbesA , Al-DamlujiA , AshworthS , BrambleM , HerbertK , HoJ , et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(9):1099-104. ">Forbes 2005</a>; <a href="./references#CD000543-bbs2-0013" title="GibsonPR , FixaB , PekárkováB , BátovskýM , Radford-SmithG , TibitanzlJ , et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(7):1017-26. ">Gibson 2006</a>; <a href="./references#CD000543-bbs2-0014" title="GoodL , NesterT , BorgenL . A double-blind comparison of controlled release mesalamine tablets and sulfasalazine in the treatment of ulcerative colitis. Gastroenterology1992;102:A630. ">Good 1992</a>; <a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a>;<a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0031" title="MaierK , FruhmorgenP , BodeJC , HellerT , Von GaisbergU , KlotzU . Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid [Erfolgreiche akutbehandlung chronisch-entzundlicher darmerkrankungen mit oraler 5-aminosalicylsaure]. Deutsche Medizinische Wochenschrift1985;110(10):363-8. ">Maier 1985</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a>; <a href="./references#CD000543-bbs2-0035" title="MihasAA , XynopoulosD , MihasTA . A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis.. Gastroenterology1988;94(5 Part 2):A303. ">Mihas 1988</a>; <a href="./references#CD000543-bbs2-0036" title="MunakataA , YoshidaY , MutoT , TsuchiyaS , FukushimaT , HiwatashiN , et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology1995;30(Suppl 8):108-11. MunakataA , YoshidaY , MutoT . Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)1994;22(Suppl 10):S2555-83. ">Munakata 1995</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0046" title="SandbornWJ , RegulaJ , FeaganB , BelousovaEA , JojicNV , LukasM , et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology2008;134(4 Suppl 1):A99. SandbornWJ , RegulaJ , FeaganBG , BelousovaE , JojicN , LukasM , et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology2009;137(6):1934-43. ">Sandborn 2009</a>; <a href="./references#CD000543-bbs2-0047" title="SandbornWJ , TravisS , MoroL , JonesR , GautilleT , BaginR , et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology2012;143(5):1218-26. ">Sandborn 2012</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>; <a href="./references#CD000543-bbs2-0051" title="SutherlandLR , RobinsonM , OnstadG , PeppercornM , GreenbergerN , GoodmanM , et al. A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Canadian Journal of Gastroenterology1990;4:463-7. ">Sutherland 1990</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>) (See <a href="./references#CD000543-sec-0114" title="">Characteristics of included studies</a>). There was one ongoing study identified from <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> (<a href="./references#CD000543-bbs2-0076" title="NCT02522767. Mesalamine 4 g sachet for the induction of remission in active, mild to moderate ulcerative colitis (UC) (Ferring Pharmaceuticals). clinicaltrials.gov/show/NCT02522767 (first received 13 August 2015). ">NCT02522767</a>). </p> <div class="figure" id="CD000543-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000543-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD000543-sec-0042"> <h4 class="title">Included studies</h4> <p>Of the 54 included studies, 16 were placebo‐controlled (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0047" title="SandbornWJ , TravisS , MoroL , JonesR , GautilleT , BaginR , et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology2012;143(5):1218-26. ">Sandborn 2012</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>;<a href="./references#CD000543-bbs2-0051" title="SutherlandLR , RobinsonM , OnstadG , PeppercornM , GreenbergerN , GoodmanM , et al. A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Canadian Journal of Gastroenterology1990;4:463-7. ">Sutherland 1990</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>). Eighteen studies compared 5‐ASA to SASP (<a href="./references#CD000543-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. In: Clinical Controversies in Inflammatory Bowel Disease. 1987:170. ">Andreoli 1987</a>; <a href="./references#CD000543-bbs2-0002" title="BresciG , CarraiM , VenturiniG , GambardellaL . Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity. International Journal of Tissue Reactions1990;12(4):243-6. ">Bresci 1990</a>; <a href="./references#CD000543-bbs2-0003" title="CaiJT , WuLF , DuQ , QianKD . Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion2001;21(10):593-5. ">Cai 2001</a>; <a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0014" title="GoodL , NesterT , BorgenL . A double-blind comparison of controlled release mesalamine tablets and sulfasalazine in the treatment of ulcerative colitis. Gastroenterology1992;102:A630. ">Good 1992</a>; <a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0031" title="MaierK , FruhmorgenP , BodeJC , HellerT , Von GaisbergU , KlotzU . Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid [Erfolgreiche akutbehandlung chronisch-entzundlicher darmerkrankungen mit oraler 5-aminosalicylsaure]. Deutsche Medizinische Wochenschrift1985;110(10):363-8. ">Maier 1985</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>; <a href="./references#CD000543-bbs2-0035" title="MihasAA , XynopoulosD , MihasTA . A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis.. Gastroenterology1988;94(5 Part 2):A303. ">Mihas 1988</a>; <a href="./references#CD000543-bbs2-0036" title="MunakataA , YoshidaY , MutoT , TsuchiyaS , FukushimaT , HiwatashiN , et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology1995;30(Suppl 8):108-11. MunakataA , YoshidaY , MutoT . Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)1994;22(Suppl 10):S2555-83. ">Munakata 1995</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>;<a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>). Five studies compared once‐daily dosing of mesalamine with conventional dosing (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). Twelve trials compared the efficacy and safety of various formulations of oral 5‐ASA (e.g. MMX mesalamine, Ipocol, Balsalazide, Pentasa, Olsalazine and 5‐ASA micropellets) to other formulations of oral 5‐ASA (e.g. Asacol, Claversal, Salofalk, Pentasa) (<a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>; <a href="./references#CD000543-bbs2-0012" title="ForbesA , Al-DamlujiA , AshworthS , BrambleM , HerbertK , HoJ , et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(9):1099-104. ">Forbes 2005</a>; <a href="./references#CD000543-bbs2-0013" title="GibsonPR , FixaB , PekárkováB , BátovskýM , Radford-SmithG , TibitanzlJ , et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(7):1017-26. ">Gibson 2006</a>; <a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>). Eleven trials were dose‐ranging studies of oral 5‐ASA (<a href="./references#CD000543-bbs2-0004" title="D'HaensG , HommesD , EngelsL , BaertF , Van der WaaijL , ConnorP , et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacology and Therapeutics2006;24(7):1087-97. ">D'Haens 2006</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>; <a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>; <a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a>; <a href="./references#CD000543-bbs2-0046" title="SandbornWJ , RegulaJ , FeaganB , BelousovaEA , JojicNV , LukasM , et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology2008;134(4 Suppl 1):A99. SandbornWJ , RegulaJ , FeaganBG , BelousovaE , JojicN , LukasM , et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology2009;137(6):1934-43. ">Sandborn 2009</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>). </p> </section> <section id="CD000543-sec-0043"> <h4 class="title">Excluded studies</h4> <p>Twenty‐two reports of 21 of these studies were excluded (See <a href="./references#CD000543-sec-0115" title="">Characteristics of excluded studies</a>). Four studies were excluded because they were not classified as RCTs (<a href="./references#CD000543-bbs2-0056" title="AhluwaliaNK , ThompsonDG , GoodmanMJ , ManiV , McIntyreJ , DaneG . Double-blind randomized trial of 4.8 g vs. 2.4 g of mesalazine for 4 weeks in the treatment of acute ulcerative colitis. Gastroenterology1992;102:A588. ">Ahluwalia 1992</a>; <a href="./references#CD000543-bbs2-0061" title="IrvineEJ , YehCH , RamseyD , StirlingAL , HigginsPD . The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2008;28(11-12):1278-86. ">Irvine 2008</a>; <a href="./references#CD000543-bbs2-0062" title="KammMA , LichtensteinGR , SandbornWJ , SchreiberS , LeesK , BarrettK , et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases2009;15(1):1-8. ">Kamm 2009</a>; <a href="./references#CD000543-bbs2-0067" title="PruittRE , GremillionDE , HerringRW , BaileyAH , FaustTW , PotterM , et al. Oral Asacol in the treatment of mild to moderate ulcerative colitis: the Nashville experience. Journal of the Tennessee Medical Association1991;84(5):237. ">Pruitt 1991</a>), seven studies were excluded because they did not have a control group (<a href="./references#CD000543-bbs2-0057" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2013;124(4 Suppl 1):A379. ">Behrens 2013</a>; <a href="./references#CD000543-bbs2-0058" title="DignassA , SchnabelR , RomatowskiJ , PavlenkoV , DorofeyevA , DorovaJ , et al. Efficacy and safety of novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterology Journal2018;6(1):138-47. ">Dignass 2018</a>; <a href="./references#CD000543-bbs2-0065" title="PaoluziP , D'AlbasioG , PeraA , Bianchi PorroG , PaoluziOA , PicaR , et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease2002;34(11):787-93. ">Paoluzi 2002</a>; <a href="./references#CD000543-bbs2-0068" title="RubinDT , CohenRD , SandbornWJ , LichtensteinGR , AxlerJ , RiddellRH , et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: A randomised, placebo-controlled trial. Journal of Crohn's &amp; Colitis2017;11(7):785-91. ">Rubin 2017</a>; <a href="./references#CD000543-bbs2-0073" title="VerniaP , MonteleoneG , GrandinettiG , VillottiG , Di GiulioE , FrieriG , et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Digestive Diseases and Sciences2000;45(5):976-81. ">Vernia 2000</a>; <a href="./references#CD000543-bbs2-0074" title="YeLN , HuangYB , ChenCX , LvW , FanYH , YangHH , et al. Combined oral and suppository treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with mild/moderate extensive or left-sided active ulcerative colitis: a randomized multi-center controlled study. Journal of Digestive Diseases2018;19(1):35. ">Ye 2018</a>; <a href="./references#CD000543-bbs2-0075" title="YoshimuraN , OkanoS , SakoM , TakazoeM . Efficacy of once a day multi matrix mesalamine formulation, lialda in patients with active mild to moderate ulcerative colitis after inadequate response to the pH-dependent release mesalamine formulation, asacol. Journal of Crohn's &amp; Colitis2018;12(1):S300. ">Yoshimura 2018</a>), two studies because they had an ineligible comparator group (<a href="./references#CD000543-bbs2-0055" title="ArdizzoneS , MaconiG , RussoA , ImbesiV , ColomboE , Bianchi PorroG . Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut2006;55(1):47-53. ">Adrizzone 2006</a>; <a href="./references#CD000543-bbs2-0060" title="GrossV , BunganicI , BelousovaEA , MikhailovaTL , KupcinskasL , KiudelisG , et al. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. Journal of Crohn's &amp; Colitis2011;5(2):129-38. ">Gross 2011</a>), four studies because they did not include an oral 5‐ASA formulation (<a href="./references#CD000543-bbs2-0063" title="LevineA , YerushalmiB , KoriM , BroideE , Mozer-GlassbergY , ShaoulR , et al. Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral Mesalamine: A prospective cohort study. Journal of Pediatric Gastroenterology and Nutrition2017;64(Suppl 1):49. LevineA , YerushalmiB , KoriM , BroideE , Mozer-GlassbergY , ShaoulR , et al. Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: A prospective cohort study. Journal of Crohn's &amp; Colitis2017;11(Suppl 1):S285. ">Levine 2017</a>; <a href="./references#CD000543-bbs2-0064" title="MahmoodA , MelleyL , FitzgeraldAJ , GhoshS , PlayfordRJ . Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(11):1357-64. ">Mahmood 2005</a>; <a href="./references#CD000543-bbs2-0069" title="SafdiM , DeMiccoM , SninskyC , BanksP , WrubleL , DerenJ , et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. American Journal of Gastroenterology1997;92(10):1867-71. ">Safdi 1997</a>; <a href="./references#CD000543-bbs2-0072" title="VecchiM , MeucciG , GionchettiP , BeltramiM , Di MaurizioP , BerettaL , et al. Oral versus combination mesalazine therapy in active ulcerative colitis: A double-blind, double-dummy, randomized multicentre study. Alimentary Pharmacology &amp; Therapeutics2001;15(2):251-6. ">Vecchi 2001</a>), two studies were not induction studies (<a href="./references#CD000543-bbs2-0066" title="ParkSK , EunCS , SeoGS , LimJ , KimTO , ParkDI . The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study. Journal of Crohn's &amp; Colitis2018;12(Suppl 1):S367. ">Park 2018</a>; <a href="./references#CD000543-bbs2-0070" title="SuzukiY , IidaM , ItoH , NishinoH , OhmoriT , AraiT , et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: A randomized, noninferiority, multi-center trial. Inflammatory Bowel Diseases2017;23(5):822-32. ">Suzuki 2017</a>), one study was a pediatric study (<a href="./references#CD000543-bbs2-0071" title="TurnerD , YerushalmiB , KoriM , BroideE , Mozer-GlassbergY , ShaoulR , et al. Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: A randomised controlled trial. Journal of Crohn's &amp; Colitis2017;11(5):527-33. ">Turner 2017</a>) and one study because the study drug included a combination of 5‐ASA and sodium hyaluronate (<a href="./references#CD000543-bbs2-0059" title="FiorinoG , SturnioloGC , BossaF , CassinottiA , SabatinoAD , GiuffridaP , et al. A phase 2a, multicenter, randomized, double-blind,parallel-group, placebo-controlled trial of IBD98-M delayed-release capsules to induce remission in patients with active and mild to moderate ulcerative colitis. Cells2019;8(6):1-11. ">Fiorino 2019</a>). </p> </section> </section> <section id="CD000543-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>We provide a summary of the 'Risk of bias' assessment in <a href="#CD000543-fig-0002">Figure 2</a>. Most of the included studies were of high methodological quality. We rated five studies at high risk of bias due to incomplete outcome data and lack of blinding. Thirty‐two of 54 included studies did not describe the method used for randomization and we rated them as unclear for this domain. Twenty‐six studies did not describe methods used for allocation concealment and we rated them as unclear for this domain. The methods used for blinding were not described in five studies, and these studies were rated as unclear. We judged 20 studies to be at unclear risk for incomplete outcome data because reasons for withdrawal were either not described or were not attributed to intervention groups. We rated six studies as unclear for selective reporting. </p> <div class="figure" id="CD000543-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000543-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD000543-sec-0045"> <h3 class="title" id="CD000543-sec-0045">Effects of interventions</h3> <p>See: <a href="./full#CD000543-tbl-0001"><b>Summary of findings 1</b> Oral 5‐ASA versus placebo for induction of remission in ulcerative colitis</a>; <a href="./full#CD000543-tbl-0002"><b>Summary of findings 2</b> Oral 5‐ASA versus SASP for induction of remission in ulcerative colitis</a>; <a href="./full#CD000543-tbl-0003"><b>Summary of findings 3</b> Once daily dosing versus conventional dosing for induction of remission in ulcerative colitis</a>; <a href="./full#CD000543-tbl-0004"><b>Summary of findings 4</b> Oral 5‐ASA versus comparator 5‐ASA for induction of remission in ulcerative colitis</a> </p> <section id="CD000543-sec-0046"> <h4 class="title">1. 5‐ASA versus placebo</h4> <section id="CD000543-sec-0047"> <h5 class="title">Failure to induce complete global or clinical remission</h5> <p>Eleven studies (2387 participants) reported treatment outcomes as failure to induce complete global or clinical remission (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>; <a href="./references#CD000543-bbs2-0047" title="SandbornWJ , TravisS , MoroL , JonesR , GautilleT , BaginR , et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology2012;143(5):1218-26. ">Sandborn 2012</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>). Seventy‐one per cent (1107/1550) of 5‐ASA participants failed to enter remission compared to 83% (695/837) of placebo participants (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.82 to 0.89; I<sup>2</sup> = 25%; high‐certainty evidence; <a href="./references#CD000543-fig-0003" title="">Analysis 1.1</a>) . There was a trend towards greater efficacy with higher doses of 5‐ASA for the 2 to 2.9 g/day (RR 0.88, 95% CI 0.82 to 0.94; I<sup>2</sup> = 27%; 956 participants, 8 studies) and the &gt; 3 g/day subgroups (RR 0.83, 95% CI 0.77 to 0.88; I<sup>2</sup> = 25%; 1200 participants, 8 studies). The five trials that involved Asacol (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>) had a pooled RR of 0.84 (95% CI 0.79 to 0.90). Two trials using MMX mesalazine (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>) had a pooled RR of 0.81 (95% CI 0.73 to 0.89). </p> </section> <section id="CD000543-sec-0048"> <h5 class="title">Failure to induce global or clinical improvement</h5> <p>Fourteen studies (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0051" title="SutherlandLR , RobinsonM , OnstadG , PeppercornM , GreenbergerN , GoodmanM , et al. A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Canadian Journal of Gastroenterology1990;4:463-7. ">Sutherland 1990</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>) (2256 participants) provided data on the failure to induce global or clinical improvement (including remission). Forty‐one per cent (605/1459) of 5‐ASA participants failed to improve clinically compared to 65% (519/797) of placebo participants (RR 0.68, 95% CI 0.61 to 0.75, I<sup>2</sup> = 47%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0004" title="">Analysis 1.2</a>).There was a trend towards greater efficacy with higher doses of 5‐ASA for all dosage subgroups: &lt; 2 g/day (RR 0.79, 95% CI 0.64 to 0.97; I<sup>2</sup> = 0%); 2 to 2.9 g/day (RR 0.77, 95% CI 0.67 to 0.88; I<sup>2</sup> = 32%); &gt; 3 g/day (RR 0.57, 95% CI 0.51 to 0.65; I<sup>2</sup> = 5%). Five trials involving Asacol (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>) had a pooled RR of 0.68 (95% CI 0.58 to 0.80). Four studies involved Olsalazine (<a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>), and resulted in a pooled RR of 0.80 (95% CI 0.65 to 0.97). Two trials using MMX mesalazine (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>) had a pooled RR of 0.64 (95% CI 0.55 to 0.75). </p> </section> <section id="CD000543-sec-0049"> <h5 class="title">Failure to induce endoscopic remission</h5> <p>Four studies (<a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>) (1154 participants) reported on failure to induce complete endoscopic remission. Fifty per cent (399/805) of 5‐ASA participants failed to enter endoscopic remission compared to 64% (223/349) of placebo participants (RR 0.77, 95% CI 0.67 to 0.89; I<sup>2</sup> = 42%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0005" title="">Analysis 1.3</a>). The doses of 3 g or more were shown to be more effective compared to the other doses (RR 0.70, 95% CI 0.56 to 0.87; I<sup>2</sup> = 51%). </p> </section> <section id="CD000543-sec-0050"> <h5 class="title">Failure to induce endoscopic improvement</h5> <p>Four studies (<a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>) (416 participants), all involving Olsalazine, reported failure to induce endoscopic remission or improvement. Forty‐four per cent (113/255) of 5‐ASA participants failed to improve endoscopically compared to 63% (102/161) of placebo participants (RR 0.71, 95% CI 0.59 to 0.86; I<sup>2</sup> = 43%; low‐certainty evidence; <a href="./references#CD000543-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD000543-sec-0051"> <h5 class="title">Adverse events</h5> <p>Eight studies (1218 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>). There was no difference in the incidence of AEs between 5‐ASA and placebo participants. Fifty‐two per cent (386/749) of 5‐ASA participants experienced at least one AE compared to 49% (228/469) of placebo participants (RR 0.95, 95% CI 0.85 to 1.07; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./references#CD000543-fig-0007" title="">Analysis 1.5</a>). Three trials that involved Asacol (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>) had a pooled RR of 1.03 (95% CI 0.87 to 1.21). Two studies that involved Olsalazine (<a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>) had a pooled RR of 1.09 (95% CI 0.55 to 2.15). Commonly‐reported AEs included: headache, nausea, abdominal pain or cramps, nasopharyngitis or symptoms of upper respiratory infection, rash. anorexia or loss of appetite, flatulence or gas, gastrointestinal disorders and fever. Diarrhea was reported in four studies involving Olsalazine (<a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>) and one study of Pentasa (<a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>). </p> </section> <section id="CD000543-sec-0052"> <h5 class="title">Serious adverse events</h5> <p>Four studies (546 participants) reported on the proportion of participants who experienced at least one SAE (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>). Two per cent (7/466) of participants in the 5‐ASA group experienced an SAE compared to 2% (6/280) of placebo participants (RR 0.53, 95% CI 0.18 to 1.56,I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD000543-fig-0008" title="">Analysis 1.6</a>). SAEs reported include aggravation of UC, malaise, abdominal abscess, pancreatitis and an inguinal hernia. </p> </section> <section id="CD000543-sec-0053"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Thirteen studies (2372 participants) reported the proportion of participants withdrawn due to AEs (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>). Withdrawals due to AEs were reported for 6% (91/1542) of 5‐ASA participants compared to 9% (73/830) of placebo participants (RR 0.72, 95% CI 0.54 to 0.97; I<sup>2</sup> = 13%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0009" title="">Analysis 1.7</a>). The pooled analysis of five Asacol trials (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>) showed a higher proportion of placebo participants (9.7%) were withdrawn due to AEs compared to Asacol participants (3.5%) (RR 0.50, 95% CI 0.30 to 0.84). However, when five Olsalazine studies (<a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>) were pooled a higher proportion of Olsalazine participants (8.8%) were withdrawn due to AEs compared to placebo (3.3%) (RR 2.58, 95% CI 1.16 to 5.70). When two MMX mesalamine studies were pooled (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>) a higher proportion of placebo participants (7.3%) were withdrawn due to AEs compared to MMX mesalamine (2.2%) (RR 0.31, 95% CI 0.14 to 0.72). An inspection of the forest plot showed the difference in withdrawals favoring 5‐ASA over placebo was driven by the large <a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a> study, which reported that worsening of UC was the most common AE leading to withdrawal. Worsening of UC leading to withdrawal was reported for 10 of 12 withdrawals in the 5‐ASA group compared to all 30 withdrawals in the placebo group (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>). A sensitivity analysis excluding <a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a> showed no difference in withdrawals due to AEs between 5‐ASA and placebo. Withdrawals due to AEs occurred in 6% (79/1402) of 5‐ASA participants compared to 6% (43/689) of placebo participants (RR 0.88, 95% CI 0.62 to 1.24; I<sup>2</sup> = 5%). The common AEs leading to withdrawal were not reported. </p> </section> <section id="CD000543-sec-0054"> <h5 class="title">Exclusions or withdrawals after study entry</h5> <p>Fifteen studies (2529 participants) reported the proportion of participants excluded or withdrawn after entry (<a href="./references#CD000543-bbs2-0008" title="FeaganB , SandbornW , D'HaensG , McDonaldJ , RutgeertsP , MunkholmP , et al. The value of a central image management system (CIMS) in the conduct of randomized controlled trials of therapy for ulcerative colitis (UC). American Journal of Gastroenterology2012;107:S579-80. FeaganBG , SandbornWJ , D’HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149-57. ">Feagan 2013</a>; <a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0017" title="HanauerS , BeshearsL , WilkinsonC . Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology1990;98(5 Part 2):A174. HanauerS , SchwartzJ , RobinsonM , RoufailW , AroraS , CelloJ , et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. American Journal of Gastroenterology1993;88(8):1188-97. HanauerS , SchwartzJ , RoufailW , RobinsonM , CelloJ , SafdiM , et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology1989;96:A195. MinerP , NostrantT , WrubleL , HinesC , JohnsonS , WilkinsonC , et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology1991;100(5 Part 2):A231. RobinsonM , CelloJ , SafdiM , SchwartzJ , RoufailW , HoopR , et al. Mesalamine (Pentasa) enhances quality of life (QofL) for ulcerative colitis (UC) patients. Gastroenterology1991;100(5 Part 2):A243. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Hanauer 1993</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>; <a href="./references#CD000543-bbs2-0037" title="PontesC , VivesR , TorresF , PanesJ . Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases2014;20(11):2004-12. ">Pontes 2014</a>; <a href="./references#CD000543-bbs2-0048" title="PruittRE , RosenAA , WrubleL , SedghiS , ShepardRD , MareyaSM , et al. Safety and tolerability of twice-daily balsalazide tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. RubinDT , RosenAA , SedghiS , ShepardRD , MareyaSM , HuangS , et al. Twice-daily balsalazide tablets improve patient quality of life after 2 and 8 weeks of treatment: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Gastroenterology2008;134(4 Suppl 1):A494. ScherlEJ , PruittR , GordonGL , LametM , ShawA , HuangS , et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology2009;104(6):1452-9. ScherlEJ , PruittRE , GordonGL , LametM , ShawAL , HuangS , et al. Twice-daily dosing of balsalazide tablets 3.3 g is safe and effective in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology2009;1:A520. ">Scherl 2009</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0051" title="SutherlandLR , RobinsonM , OnstadG , PeppercornM , GreenbergerN , GoodmanM , et al. A double-blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Canadian Journal of Gastroenterology1990;4:463-7. ">Sutherland 1990</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>). Twenty‐four per cent (388/1642) of 5‐ASA participants were withdrawn or excluded after entry compared to 37% (332/887) of placebo participants (R 0.61, 95% CI 0.51 to 0.72; I<sup>2</sup> = 37%; See <a href="./references#CD000543-fig-0010" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD000543-sec-0055"> <h4 class="title">2. 5‐ASA versus sulfasalazine</h4> <section id="CD000543-sec-0056"> <h5 class="title">Failure to induce complete global or clinical remission</h5> <p>The failure to induce complete global or clinical remission was reported in eight studies (526 participants) (<a href="./references#CD000543-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. In: Clinical Controversies in Inflammatory Bowel Disease. 1987:170. ">Andreoli 1987</a>; <a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>; <a href="./references#CD000543-bbs2-0031" title="MaierK , FruhmorgenP , BodeJC , HellerT , Von GaisbergU , KlotzU . Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid [Erfolgreiche akutbehandlung chronisch-entzundlicher darmerkrankungen mit oraler 5-aminosalicylsaure]. Deutsche Medizinische Wochenschrift1985;110(10):363-8. ">Maier 1985</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>). Fifty‐four per cent (150/279) of 5‐ASA participants failed to enter remission compared to 58% (144/247) of SASP participants (RR 0.90, 95% CI 0.77 to 1.04; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0011" title="">Analysis 2.1</a>). Two studies involving Claversal (<a href="./references#CD000543-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. In: Clinical Controversies in Inflammatory Bowel Disease. 1987:170. ">Andreoli 1987</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>) had a pooled RR of 1.00 (95% CI 0.83 to 1.21). Two studies involving Balsalazide (<a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>) had a pooled RR of 0.93 (95% CI 0.57 to 1.51). Two studies involving Olsalazine (<a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>) had a pooled 0.66 (95% CI 0.43 to 1.02). </p> </section> <section id="CD000543-sec-0057"> <h5 class="title">Failure to induce global or clinical improvement</h5> <p>Fourteen studies (<a href="./references#CD000543-bbs2-0002" title="BresciG , CarraiM , VenturiniG , GambardellaL . Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity. International Journal of Tissue Reactions1990;12(4):243-6. ">Bresci 1990</a>; <a href="./references#CD000543-bbs2-0003" title="CaiJT , WuLF , DuQ , QianKD . Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion2001;21(10):593-5. ">Cai 2001</a>; <a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0014" title="GoodL , NesterT , BorgenL . A double-blind comparison of controlled release mesalamine tablets and sulfasalazine in the treatment of ulcerative colitis. Gastroenterology1992;102:A630. ">Good 1992</a>; <a href="./references#CD000543-bbs2-0031" title="MaierK , FruhmorgenP , BodeJC , HellerT , Von GaisbergU , KlotzU . Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid [Erfolgreiche akutbehandlung chronisch-entzundlicher darmerkrankungen mit oraler 5-aminosalicylsaure]. Deutsche Medizinische Wochenschrift1985;110(10):363-8. ">Maier 1985</a>; <a href="./references#CD000543-bbs2-0035" title="MihasAA , XynopoulosD , MihasTA . A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis.. Gastroenterology1988;94(5 Part 2):A303. ">Mihas 1988</a>; <a href="./references#CD000543-bbs2-0036" title="MunakataA , YoshidaY , MutoT , TsuchiyaS , FukushimaT , HiwatashiN , et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology1995;30(Suppl 8):108-11. MunakataA , YoshidaY , MutoT . Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)1994;22(Suppl 10):S2555-83. ">Munakata 1995</a>; <a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>) (1053 participants) reported failure to induce global or clinical improvement (including remission). Thirty‐seven per cent (227/608) of 5‐ASA participants failed to improve compared to 47% (208/445) of SASP participants (RR 0.88, 95% CI 0.76 to 1.01; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./references#CD000543-fig-0012" title="">Analysis 2.2</a>). Six Olsalazine trials (<a href="./references#CD000543-bbs2-0003" title="CaiJT , WuLF , DuQ , QianKD . Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion2001;21(10):593-5. ">Cai 2001</a>; <a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>) had a pooled RR of 0.76 (95% CI 0.57 to 1.00). </p> </section> <section id="CD000543-sec-0058"> <h5 class="title">Failure to induce endoscopic remission</h5> <p>Since only two studies (<a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>) reported failure to induce complete endoscopic remission, we did not conduct a meta‐analysis for this outcome. We did not pool the studies, as they used different indices to measure endoscopic remission. Neither study showed significant differences in complete endoscopic remission between 5‐ASA and SASP. </p> </section> <section id="CD000543-sec-0059"> <h5 class="title">Failure to induce endoscopic improvement</h5> <p>Six studies (<a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0036" title="MunakataA , YoshidaY , MutoT , TsuchiyaS , FukushimaT , HiwatashiN , et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology1995;30(Suppl 8):108-11. MunakataA , YoshidaY , MutoT . Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)1994;22(Suppl 10):S2555-83. ">Munakata 1995</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>) (362 participants) provided data on failure to induce endoscopic improvement (including remission). Forty‐one per cent (78/189) of 5‐ASA participants failed to improve endoscopically compared to 45% (78/173) of SASP participants: RR 0.82, 95% CI 0.65 to 1.02; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0013" title="">Analysis 2.3</a>). Three trials involving Olsalazine (<a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>) had a pooled RR of 0.93 (95% CI 0.62 to 1.39). </p> </section> <section id="CD000543-sec-0060"> <h5 class="title">Failure to adhere to medication regimen</h5> <p>No studies reported this outcome.</p> </section> <section id="CD000543-sec-0061"> <h5 class="title">Adverse events</h5> <p>Twelve studies (909 participants) reported the proportion of participants who experienced at last one AE (<a href="./references#CD000543-bbs2-0002" title="BresciG , CarraiM , VenturiniG , GambardellaL . Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity. International Journal of Tissue Reactions1990;12(4):243-6. ">Bresci 1990</a>; <a href="./references#CD000543-bbs2-0003" title="CaiJT , WuLF , DuQ , QianKD . Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion2001;21(10):593-5. ">Cai 2001</a>; <a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>; <a href="./references#CD000543-bbs2-0035" title="MihasAA , XynopoulosD , MihasTA . A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis.. Gastroenterology1988;94(5 Part 2):A303. ">Mihas 1988</a>; <a href="./references#CD000543-bbs2-0036" title="MunakataA , YoshidaY , MutoT , TsuchiyaS , FukushimaT , HiwatashiN , et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology1995;30(Suppl 8):108-11. MunakataA , YoshidaY , MutoT . Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)1994;22(Suppl 10):S2555-83. ">Munakata 1995</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>). It should be noted that, with two exceptions (<a href="./references#CD000543-bbs2-0035" title="MihasAA , XynopoulosD , MihasTA . A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis.. Gastroenterology1988;94(5 Part 2):A303. ">Mihas 1988</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>), the inclusion criteria for entry included tolerance of SASP. Nevertheless, SASP participants were significantly more likely than 5‐ASA participants to experience an AE. Fourteen per cent (72/498) of 5‐ASA participants experienced at least one AE compared to 29% (118/411) of SASP participants (RR 0.48, 95% CI 0.36 to 0.63; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0014" title="">Analysis 2.4</a>). Five Olsalazine trials (<a href="./references#CD000543-bbs2-0003" title="CaiJT , WuLF , DuQ , QianKD . Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial. Chinese Journal of Digestion2001;21(10):593-5. ">Cai 2001</a>; <a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>) had a combined RR of 0.48 (95% CI 0.32 to 0.71), and two Balsalazide trials (<a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>) had a combined RR of 0.16 (95% CI 0.05 to 0.52).Commonly‐reported AEs included: nausea, headache, dyspepsia, vomiting, abdominal pain and rash. Diarrhea was reported in three studies involving Olsalazine (<a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0024" title="JiangXL , CuiHF . Different therapy for different types of ulcerative colitis. World Journal of Gastroenterology2004;10(10):1513-20. ">Jiang 2004</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>). </p> </section> <section id="CD000543-sec-0062"> <h5 class="title">Serious adverse events</h5> <p>Two studies (107 participants) reported on the proportion of participants who experienced at least one SAE (<a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>). There was no difference between the 5‐ASA and SASP groups. Six per cent of participants (3/54) in the 5‐ASA group experienced an SAE compared to 4% (2/53) of SASP participants (RR 1.36, 95% CI 0.28 to 6.52; low‐certainty evidence; <a href="./references#CD000543-fig-0015" title="">Analysis 2.5</a>). SAEs reported include erythematous rash, venous thrombosis, carcinoma, acute pancreatitis, rheumatoid arthritis and erythema nodosum. </p> </section> <section id="CD000543-sec-0063"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Ten studies (640 participants) reported the proportion of participants withdrawn due to AEs (<a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>; <a href="./references#CD000543-bbs2-0035" title="MihasAA , XynopoulosD , MihasTA . A prospective trial of oral 5-aminosalicylic acid vs sulfasalazine in ulcerative colitis.. Gastroenterology1988;94(5 Part 2):A303. ">Mihas 1988</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>). SASP resulted in a higher proportion of participants withdrawn due to AEs.Thirteen per cent (39/303) of SASP participants were withdrawn due to AEs compared to 4% (15/337) of 5‐ASA participants (RR 0.40, 95% CI 0.24 to 0.68; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0016" title="">Analysis 2.6</a>). When four Olsalazine trials were combined (<a href="./references#CD000543-bbs2-0006" title="EweK , EckhardtV , KanzlerG . Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects. Scandinavian Journal of Gastroenterology1988;23(Suppl 148):70-5. ">Ewe 1988</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0039" title="QianLP , LinGJ , XuSR , DingWQ . Clinical effect of olsalazine sodium capsule in the treatment of ulcerative colitis. Fudan University Journal of Medical Sciences2004;31(4):421-4. ">Qian 2004</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>), the RR was 0.63 (95% CI 0.24 to 1.66). The pooling of two Balsalazide trials (<a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>) had a combined RR of 0.16 (95% CI 0.05 to 0.52).The common AEs leading to withdrawal include nausea, headaches and rashes. </p> </section> <section id="CD000543-sec-0064"> <h5 class="title">Exclusions or withdrawals after study entry</h5> <p>Ten studies (701 participants) reported the proportion of participants excluded or withdrawn after entry (<a href="./references#CD000543-bbs2-0001" title="AndreoliA , CosintinoR , TrottiR , BerriF , PranteraC . 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission. In: Clinical Controversies in Inflammatory Bowel Disease. 1987:170. ">Andreoli 1987</a>; <a href="./references#CD000543-bbs2-0010" title="FleigWE , LaudageG , SommerH , WellmanW , StangeEF , RiemannJ . Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion1988;40(3):173-80. ">Fleig 1988</a>; <a href="./references#CD000543-bbs2-0016" title="GreenJR , MansfieldJC , GibsonJA , KerrGD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):61-8. GreenJR , SwanCH , RowlinsonAE , GibsonJA , BrownP , KerrGD , et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology1993;104(4 Part 2):709. ">Green 2002</a>; <a href="./references#CD000543-bbs2-0032" title="MansfieldJC , GiafferMH , CannPA , McKennaD , ThorntonPC . A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2002;16(1):69-77. ">Mansfield 2002</a>; <a href="./references#CD000543-bbs2-0036" title="MunakataA , YoshidaY , MutoT , TsuchiyaS , FukushimaT , HiwatashiN , et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Journal of Gastroenterology1995;30(Suppl 8):108-11. MunakataA , YoshidaY , MutoT . Clinical efficacy of oral controlled-release mesalazine, N-5ASA on ulcerative colitis: double-blind comparative study in comparison with salazosulphapyridineu. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)1994;22(Suppl 10):S2555-83. ">Munakata 1995</a>; <a href="./references#CD000543-bbs2-0040" title="RachmelewitzD . Mesalazine (5-ASA) is as effective as sulfasalazine (SZ) in the treatment of active ulcerative colitis (UC). Gastroenterology1988;94(5 Part 2):A362. RachmilewitzD . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82-6. ">Rachmilewitz 1989</a>; <a href="./references#CD000543-bbs2-0042" title="RaoSS , DundasSA , HoldsworthCD , CannPA , PalmerKR , CorbettCL . Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut1989;30(5):675-9. RaoSS , HoldsworthCD , PalmerKL , CannPA , DundasSA , CorbettCL . Olsalazine versus sulphasalazine (SASP) in first attacks of ulcerative colitis (UC): a double blind study. Gut1988;29:A705. ">Rao 1989</a>; <a href="./references#CD000543-bbs2-0043" title="RijkMCM , TongersonJH . The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology1991;100:A243. ">Rijk 1991</a>; <a href="./references#CD000543-bbs2-0044" title="RileySA , ManiV , GoodmanMJ , HerdME , DuttS , TurnbergA . Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut1988;29(5):669-74. RileySA , ManiV , GoodmanMJ , TurnbergLA . Delayed-release 5-aminosalicylic acid (5-ASA) and sulphasalazine (SSZ) in the treatment of mild to moderate ulcerative colitis (UC) relapse. Gut1987;28:A1329. ">Riley 1988</a>; <a href="./references#CD000543-bbs2-0053" title="WilloughbyCP , CowanRE , GouldSR , MachellRJ , StewartJB . Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scandinavian Journal of Gastroenterology1988;148:40-4. ">Willoughby 1988</a>).Twenty‐six per cent (86/337) of SASP participants were withdrawn or excluded after entry compared to 19% (70/364) of 5‐ASA participants (RR 0.76, 95% CI 0.58 to 0.99; I<sup>2</sup> = 28%; <a href="./references#CD000543-fig-0017" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD000543-sec-0065"> <h4 class="title">3. Once‐daily dosing versus conventional dosing</h4> <section id="CD000543-sec-0066"> <h5 class="title">Failure to induce complete global or clinical remission</h5> <p>Five studies (1761 participants) reported treatment outcomes for failure to induce complete global or clinical remission (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). Sixty per cent (533/881) of conventionally‐dosed 5‐ASA participants failed to enter remission compared to 61% (538/880) of participants who were dosed once daily (RR 0.99, 95% CI 0.93 to 1.06; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./references#CD000543-fig-0018" title="">Analysis 3.1</a>). None of the subgroup comparisons by formulation showed any differences in efficacy between once‐daily dosing and conventional dosing. However, only five formulations were evaluated in this pooled analysis. </p> </section> <section id="CD000543-sec-0067"> <h5 class="title">Failure to induce global or clinical improvement</h5> <p>Three studies (564 participants) reported treatment outcomes for failure to induce global or clinical improvement including remission (<a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). Thirty‐seven per cent (104/283) of conventionally‐dosed 5‐ASA participants failed to improve clinically compared to 28% (79/281) of participants who were dosed once daily (RR 0.74, 95% CI 0.49 to 1.10; I<sup>2</sup> = 59%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0019" title="">Analysis 3.2</a>). A visual inspection of the forest plot indicated that <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a> was the likely source of the heterogeneity. When we performed a sensitivity analysis excluding this study at high risk of bias the I<sup>2</sup> value dropped to 0%. Forty‐six per cent (82/179) of conventionally‐dosed 5‐ASA participants failed to improve clinically compared to 40% (71/179) of participants who were dosed once daily (RR 0.87, 95% CI 0.68 to 1.10; I<sup>2</sup> = 0%; <a href="./references#CD000543-fig-0020" title="">Analysis 3.3</a>). </p> </section> <section id="CD000543-sec-0068"> <h5 class="title">Failure to induce endoscopic remission</h5> <p>One study (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>) (817 participants) reported on the failure to induce endoscopic remission. Eighty‐nine per cent (364/408) of conventionally‐dosed participants failed to induce endoscopic remission compared to 91% (373/409) of once‐daily participants (RR 1.02, 95% CI 0.98 to 1.07; high‐certainty evidence; <a href="./references#CD000543-fig-0021" title="">Analysis 3.4</a>). </p> </section> <section id="CD000543-sec-0069"> <h5 class="title">Failure to induce endoscopic improvement</h5> <p>One study (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>) (817 participants) reported on the failure to induce endoscopic response. Fifty‐two percent (212/408) of conventionally‐dosed participants failed to induce endoscopic response compared to 55% (224/409) of participants in the once‐daily group (RR 1.05, 95% CI 0 0.93 to 1.20) (<a href="./references#CD000543-fig-0022" title="">Analysis 3.5</a>). </p> </section> <section id="CD000543-sec-0070"> <h5 class="title">Failure to adhere to medication regimen</h5> <p>Two studies (358 participants) provided dichotomous data for failure to adhere to the medication regimen at study endpoint (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). Eight per cent (15/179) of once‐daily dosed participants compared to 6% (11/179) of conventionally‐dosed participants failed to adhere to the medication regimen (RR 1.36, 95% CI 0.64 to 2.86; I<sup>2</sup> = 34%; low‐certainty evidence; <a href="./references#CD000543-fig-0023" title="">Analysis 3.6</a>). Only one study (<a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>) reported on a continuous outcome for compliance with medication (MD −4.00, 95% CI −17.38 to 9.38; <a href="./references#CD000543-fig-0024" title="">Analysis 3.7</a>). </p> </section> <section id="CD000543-sec-0071"> <h5 class="title">Adverse events</h5> <p>Four studies (1586 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). Thirty‐three per cent (259/796) of participants who were dosed once daily experienced at least one AE compared to 32% (251/790) of conventionally‐dosed participants (RR 1.02, 95% CI 0.89 to 1.18; I<sup>2</sup> = 37%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0025" title="">Analysis 3.8</a>). Common AEs included flatulence, abdominal pain, nausea, diarrhea, nasopharyngitis, dyspepsia, headache and worsening of UC. </p> </section> <section id="CD000543-sec-0072"> <h5 class="title">Serious adverse events</h5> <p>Four studies (1586 participants) reported on the proportion of participants who experienced at least one SAE (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>).Two per cent (19/796) of participants in the once‐daily group experienced an SAE compared to 2% (14/790) of participants in the conventional‐dosing group (RR 1.34, 95% CI 0.68 to 2.66; low‐certainty evidence; <a href="./references#CD000543-fig-0026" title="">Analysis 3.9</a>). SAEs reported include pancreatitis, hepatitis, polyuria, chromaturia, upper respiratory tract infection and measles. </p> </section> <section id="CD000543-sec-0073"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Five studies (1757 participants) reported the proportion of participants withdrawn due to AEs (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>).There was no difference in the proportion of participants withdrawn due to AEs between once‐daily and conventionally‐dosed participants. Three per cent (29/876) of conventionally‐dosed participants were withdrawn due to AEs compared to 3% (26/881) of participants dosed once daily (RR 0.89, 95% CI 0.54 to 1.49; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD000543-fig-0027" title="">Analysis 3.10</a>). The common AEs leading to withdrawal were not reported. </p> </section> <section id="CD000543-sec-0074"> <h5 class="title">Withdrawals or exclusions after study entry</h5> <p>Four studies (944 participants) reported on the proportion of participants excluded or withdrawn after entry (<a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). There was no difference in the proportion of participants excluded or withdrawn after entry between once‐daily and conventionally‐dosed participants. Fourteen per cent (67/472) of participants dosed once daily were excluded or withdrawn after entry compared to 14% (66/472) of conventionally‐dosed participants (RR 1.02, 95% CI 0.74 to 1.39; I<sup>2</sup> = 0%; <a href="./references#CD000543-fig-0028" title="">Analysis 3.11</a>). </p> </section> </section> <section id="CD000543-sec-0075"> <h4 class="title">4. 5‐ASA versus comparator 5‐ASA</h4> <section id="CD000543-sec-0076"> <h5 class="title">Failure to induce complete global or clinical remission</h5> <p>Eleven studies (1968 participants) reported treatment outcomes for failure to induce complete global or clinical remission (<a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>; <a href="./references#CD000543-bbs2-0012" title="ForbesA , Al-DamlujiA , AshworthS , BrambleM , HerbertK , HoJ , et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(9):1099-104. ">Forbes 2005</a>; <a href="./references#CD000543-bbs2-0013" title="GibsonPR , FixaB , PekárkováB , BátovskýM , Radford-SmithG , TibitanzlJ , et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(7):1017-26. ">Gibson 2006</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>). 5‐ASA formulations included MMX mesalamine, Ipocol, Balsalazide, Pentasa, Olsalazine and 5‐ASA micropellets. Comparator 5‐ASA formulations included Asacol, Claversal, Salofalk, and Pentasa. </p> <p>We did not include <a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a> in the pooled analysis because it enrolled participants with moderate‐to‐severe disease, whereas the other studies in the pooled analysis enrolled participants with mild to moderately‐active UC. <a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a> also allowed the use of rectal steroid foam to relieve active symptoms, which was not allowed in the other 5‐ASA controlled studies. Fifty per cent (507/1022) of participants in the 5‐ASA group failed to enter remission compared to 52% (491/946) of participants in the 5‐ASA comparator group (RR 0.94, 95% CI 0.86 to 1.02; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0029" title="">Analysis 4.1</a>). However, a sensitivity analysis excluding the two studies at high risk of bias (<a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>) produced similar results (1681 participants, 9 studies). Forty‐eight per cent (405/842) of participants in the 5‐ASA group failed to enter remission compared to 50% (424/839) of participants in the 5‐ASA comparator group (RR 0.95, 95% CI 0.87 to 1.04; I<sup>2</sup> = 0%). <a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a> compared Balsalazide 6.75 g/day (n = 50) to Asacol 2.4 g/day (n = 49). At eight weeks 22% of participants in the Balsalazide group failed to enter remission compared to 45% of participants in the Asacol group (RR 0.49; 95% CI 0.27 to 0.90). </p> </section> <section id="CD000543-sec-0077"> <h5 class="title">Failure to induce global or clinical improvement</h5> <p>Eight studies (1647 participants) reported treatment outcomes for failure to induce global or clinical improvement including remission (<a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>; <a href="./references#CD000543-bbs2-0013" title="GibsonPR , FixaB , PekárkováB , BátovskýM , Radford-SmithG , TibitanzlJ , et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(7):1017-26. ">Gibson 2006</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>). Thirty per cent (260/862) of participants in the 5‐ASA group failed to improve clinically compared to 35% (272/785) of participants in the 5‐ASA comparator group (RR 0.89, 95% CI 0.77 to 1.01; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0031" title="">Analysis 4.3</a>). The various formulations of 5‐ASA included Balsalazide, Pentasa, Olsalazine, MMX mesalazine, and 5‐ASA micropellets; the comparator formulations of 5‐ASA included Asacol, Claversal, Salofalk and Pentasa. However, a sensitivity analysis excluding the study at high risk of bias (<a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>) produced similar results (1420 participants, 7 studies). Thirty‐two per cent (226/712) of participants in the 5‐ASA group failed to improve clinically compared to 35% (247/708) of participants in the 5‐ASA comparator group (RR 0.91, 95% CI 0.79 to 1.05; I<sup>2</sup> = 0%; <a href="./references#CD000543-fig-0032" title="">Analysis 4.4</a>). </p> </section> <section id="CD000543-sec-0078"> <h5 class="title">Failure to induce endoscopic remission</h5> <p>No studies reported this outcome.</p> </section> <section id="CD000543-sec-0079"> <h5 class="title">Failure to induce endoscopic improvement</h5> <p>No studies reported this outcome.</p> </section> <section id="CD000543-sec-0080"> <h5 class="title">Failure to adhere to medication regimen</h5> <p>No studies reported this outcome.</p> </section> <section id="CD000543-sec-0081"> <h5 class="title">Adverse events</h5> <p>Nine studies (1576 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000543-bbs2-0012" title="ForbesA , Al-DamlujiA , AshworthS , BrambleM , HerbertK , HoJ , et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(9):1099-104. ">Forbes 2005</a>; <a href="./references#CD000543-bbs2-0013" title="GibsonPR , FixaB , PekárkováB , BátovskýM , Radford-SmithG , TibitanzlJ , et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(7):1017-26. ">Gibson 2006</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>). The pooled risk ratio showed no difference in the incidence of AEs between various formulations of 5‐ASA (including Balsalazide, Pentasa, Olsalazine, Ipocol and 5‐ASA micropellets) and comparator formulations of 5‐ASA (including Asacol, Claversal and Salofalk). Forty‐six per cent (365/792) of participants in the 5‐ASA group experienced at least one AE compared to 46% (358/784) of participants in the 5‐ASA comparator group (RR 1.01, 95% CI 0.92 to 1.12; I<sup>2</sup> = 10%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0033" title="">Analysis 4.5</a>). Common AEs included headache, abdominal pain, nausea, flatulence, diarrhea, nasopharyngitis, dyspepsia, vomiting and the worsening of UC. </p> </section> <section id="CD000543-sec-0082"> <h5 class="title">Serious adverse events</h5> <p>Four studies (677 participants) reported on the proportion of participants who experienced at least one SAE (<a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>). Two per cent (6/343) of participants experienced an SAE in the 5‐ASA group compared to 3% (10/334) of participants in the comparator 5‐ASA group. There was no difference between the 5‐ASA versus comparator 5‐ASA group (RR 0.59, 95% CI 0.22 to 1.56; low‐certainty evidence; <a href="./references#CD000543-fig-0034" title="">Analysis 4.6</a>). SAEs reported include aggravation of UC and a colonic polyp. </p> </section> <section id="CD000543-sec-0083"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Nine studies (1489 participants) reported the proportion of participants withdrawn due to AEs (<a href="./references#CD000543-bbs2-0012" title="ForbesA , Al-DamlujiA , AshworthS , BrambleM , HerbertK , HoJ , et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(9):1099-104. ">Forbes 2005</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>). The pooled risk ratio showed no difference in withdrawals due to AEs between various formulations of 5‐ASA (including Balsalazide, Pentasa, Olsalazine, MMX mesalazine; Ipocol and 5‐ASA micropellets) and comparator formulations of 5‐ASA (including Asacol, Claversal and Salofalk). Four per cent (28/749) of participants in the 5‐ASA group were withdrawn due to AEs compared to 4% (29/740) of participants in the 5‐ASA comparator group (RR 0.94, 95% CI 0.57 to 1.54; I<sup>2</sup> = 15%; moderate‐certainty evidence; <a href="./references#CD000543-fig-0035" title="">Analysis 4.7</a>). The common AEs leading to withdrawal include abdominal pain, rashes and cephalea. </p> </section> <section id="CD000543-sec-0084"> <h5 class="title">Withdrawals or exclusions following study entry</h5> <p>Ten studies (1574 participants) reported the proportion of participants excluded or withdrawn after entry (<a href="./references#CD000543-bbs2-0012" title="ForbesA , Al-DamlujiA , AshworthS , BrambleM , HerbertK , HoJ , et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(9):1099-104. ">Forbes 2005</a>; <a href="./references#CD000543-bbs2-0013" title="GibsonPR , FixaB , PekárkováB , BátovskýM , Radford-SmithG , TibitanzlJ , et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(7):1017-26. ">Gibson 2006</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0026" title="KruisW , BrandesJW , SchreiberS , TheuerD , KrakampB , SchutzE , et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1998;12(8):707-15. KruisW , SchreiberS , TheuerD , SchutzE , KrakampB , OttoP , et al. Comparison of an azoboundamino salicylate (olsalazine) vs. a coated aminosalicylate (mesalamine) for active ulcerative colitis. Gastroenterology1996;110(4):942. ">Kruis 1998</a>; <a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0033" title="MarakhouskiY , FixaB , HolomanJ , HulekP , LukasM , BatovskyM , et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(2):133-40. MarakhouskiY , FixaB , HolomanJ . Erratum: a double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2005;21(6):793. ">Marakhouski 2005</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>; <a href="./references#CD000543-bbs2-0041" title="BehrensC , BiasP , MalchowH , RaedlerA . Mesalazine (5-ASA) micropellets show comparable efficacy and tolerability as mesalazine tablets in patients with ulcerative colitis. A prospective, multi-national, randomised, double-blind, active-controlled clinical phase II study. Gastroenterology2003;124(4 Suppl 1):A379. RaedlerA , BehrensC , BiasP . Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. Alimentary Pharmacology &amp; Therapeutics2004;20(11-12):1353-63. ">Raedler 2004</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>). The pooled risk ratio showed no difference in exclusions or withdrawals after entry between various formulations of 5‐ASA (including Balsalazide, Pentasa, Olsalazine, MMX mesalazine, Ipocol and 5‐ASA micropellets) and comparator formulations of 5‐ASA (including Asacol, Claversal and Salofalk). Eighteen per cent (144/792) of participants in the 5‐ASA group were excluded or withdrawn after entry compared to 18% (143/782) of participants in the 5‐ASA comparator group (RR 0.99, 95% CI 0.80 to 1.22; I<sup>2</sup> = 0%; <a href="./references#CD000543-fig-0036" title="">Analysis 4.8</a>). </p> </section> </section> <section id="CD000543-sec-0085"> <h4 class="title">5. High‐dose versus low‐dose 5‐ASA</h4> <section id="CD000543-sec-0086"> <h5 class="title">Failure to induce complete global or clinical remission</h5> <p>Several randomized trials have looked at dose‐ranging for various formulations of 5‐ASA (e.g. Asacol, Salofalk, Pentasa, MMX mesalamine).<br/>Two studies examined the efficacy of various doses of Salofalk or Pentasa for induction of global or clinical remission in participants with mild or moderately‐active UC (<a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>). <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a> found no difference in efficacy between Salofalk 4.5 g/day compared to 3 g/day (RR 1.35, 95% CI 0.96 to 1.89; 213 participants; <a href="./references#CD000543-fig-0037" title="">Analysis 5.1</a>) or 1.5 g/day (RR 0.91, 95% CI 0.69 to 1.22; 212 participants; <a href="./references#CD000543-fig-0037" title="">Analysis 5.1</a>). In <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a> 34% (36/107) of participants in the 3 g/day group failed to enter remission compared to 50% (51/103) of participants in the 1.5 g/day group (RR 0.68, 95% CI 0.49 to 0.95). <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a> examined the efficacy of Pentasa 4 g/day compared to 2.25 g/day in participants with moderately‐active UC and found 78% (47/60) in the 4 g group compared to 86% (54/63) in the 2.25 g group failed to achieve global or clinical remission (RR 0.91, 95% CI 0.77 to 1.08; <a href="./references#CD000543-fig-0037" title="">Analysis 5.1</a>).<br/><br/><a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a> compared Asacol 3.6 g/day with Asacol 2.4 g/day. Fifty‐five per cent (36/65) of participants in the 3.6 g/day Asacol group failed to enter remission compared to 70% (46/66) of participants in the 2.4 g/day dose group (RR 0.79, 95% CI 0.61 to 1.04). </p> <p><a href="./references#CD000543-bbs2-0004" title="D'HaensG , HommesD , EngelsL , BaertF , Van der WaaijL , ConnorP , et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacology and Therapeutics2006;24(7):1087-97. ">D'Haens 2006</a> and <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a> investigated the efficacy of MMX mesalamine 2.4 g/day dosed once daily versus 4.8 g/day dosed once daily for induction of remission in active UC. Sixty‐one per cent (59/96) of participants in the 4.8 g/day group failed to enter remission compared to 60% (59/98) of participants in the 2.4 g/day group (RR 1.03, 95% CI 0.82 to 1.29, I<sup>2</sup> = 0%). </p> </section> <section id="CD000543-sec-0087"> <h5 class="title">Failure to induce global or clinical improvement</h5> <p>Six studies examined the efficacy of various doses of Asacol for global or clinical improvement including remission in participants with mild or moderately‐active UC (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>; <a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a>; <a href="./references#CD000543-bbs2-0046" title="SandbornWJ , RegulaJ , FeaganB , BelousovaEA , JojicNV , LukasM , et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology2008;134(4 Suppl 1):A99. SandbornWJ , RegulaJ , FeaganBG , BelousovaE , JojicN , LukasM , et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology2009;137(6):1934-43. ">Sandborn 2009</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>).<br/>In <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a> 26% (10/38) in the 4.8 g/day group compared to 73% (8/11) in the 1.6 g/day group failed to induce clinical remission or improvement (RR 0.36, 95% CI 0.19 to 0.69; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>).<br/><a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a> found 29% (7/24) of the 3.6 g/day dosing group compared to 48% (12/25) of the 1.2 g/day dosing group failed to induce clinical remission or improvement (RR 0.61, 95% CI 0.29 to 1.28; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>).<br/>A pooled analysis of two studies (<a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>) found that 55% (42/77) of the 2.4 g/day group compared to 59% (46/78) of the 1.6 or 1.2 g/day group failed to induce clinical remission or improvement (RR 0.92, 95% CI 0.70 to 1.21; I<sup>2</sup> = 0%; 155 participants; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>).<br/>A pooled analysis of two studies (<a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a>; <a href="./references#CD000543-bbs2-0023" title="ItoH , IidaM , MatsumotoT , SuzukiY , KoyamaH , YoshidaT , et al. A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease. Gastroenterology2010;1:S166. ItoH , IidaM , MatsumotoT , SuzukiY , SasakiH , YoshidaT , et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases2010;16(9):1567-74. ">Ito 2010</a>) found 35% (31/89) of the 3.6 g/day group failed to induce clinical remission or improvement compared with 51% (46/90) of participants in the 2.4 g/day group (RR 0.68, 95% CI 0.48 to 0.97; I<sup>2</sup> = 0%; 179 participants; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>). </p> <p>A pooled analysis of the ASCEND studies (I, II and III; 1459 participants) found no difference in clinical improvement between Asacol 4.8 g/day and 2.4 g/day. Thirty‐seven per cent (266/727) of participants in the 4.8 g/day group failed to improve clinically compared to 41% (302/732) of participants in the 2.4 g/day group (RR 0.89, 95% CI 0.78 to 1.01; I<sup>2</sup> = 0%; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>).<br/><br/>Subgroup analyses indicated that participants with moderate disease may benefit from the higher dose of 4.8 g/day (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>), particularly among participants previously treated with corticosteroids, oral 5‐ASA, rectal therapies or multiple UC medications (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>; <a href="./references#CD000543-bbs2-0046" title="SandbornWJ , RegulaJ , FeaganB , BelousovaEA , JojicNV , LukasM , et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology2008;134(4 Suppl 1):A99. SandbornWJ , RegulaJ , FeaganBG , BelousovaE , JojicN , LukasM , et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology2009;137(6):1934-43. ">Sandborn 2009</a>). </p> <p><a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a> provided data for the failure to induce global/clinical remission or improvement. Thirty‐five per cent (30/85) of participants in the 4.8 g/day group failed to improve clinically compared to 39% (33/84) of participants in the 2.4 g/day group (RR 0.90, 95% CI 0.61 to 1.33; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>).<br/><br/><a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a> examined the efficacy of Pentasa 4 g/day compared to 2.25 g/day in participants with moderately‐active UC. Twenty‐five per cent (15/60) of participants in the 4 g/day group failed to improve clinically compared to 57% (36/63) of participants in the 2.25 g/day group (RR 0.44, 95% CI 0.27 to 0.71; <a href="./references#CD000543-fig-0038" title="">Analysis 5.2</a>). </p> </section> <section id="CD000543-sec-0088"> <h5 class="title">Failure to induce endoscopic remission</h5> <p>No studies reported this outcome.</p> </section> <section id="CD000543-sec-0089"> <h5 class="title">Failure to induce endoscopic improvement</h5> <p>No studies reported this outcome.</p> </section> <section id="CD000543-sec-0090"> <h5 class="title">Failure to adhere to medication regimen</h5> <p>No studies reported this outcome</p> </section> <section id="CD000543-sec-0091"> <h5 class="title">Adverse events</h5> <p>Three dose‐ranging studies (807 participants) reported the proportion of participants who experienced at least one AE (<a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>). No differences in AE rates were found across any of the dosing subgroups: Asacol 4.8 g versus 1.6 g/day (RR 0.76, 95% CI 0.48 to 1.21; 49 participants); Salofalk 4.5 g versus 3 g/day (RR 0.96, 95% CI 0.78 to 1.20; 213 participants); Salofalk 4.5 g versus 1.5 g/day (RR 0.96, 95% CI 0.77 to 1.19; 209 participants); Salofalk 3 g versus 1.5 g/day (RR 1.04, 95% CI 0.84 to 1.29; 213 participants); Pentasa 4 g versus 2.25 g/day (RR 0.93, 95% CI 0.78 to 1.11; 123 participants). The most common AE reported in <a href="./references#CD000543-bbs2-0004" title="D'HaensG , HommesD , EngelsL , BaertF , Van der WaaijL , ConnorP , et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacology and Therapeutics2006;24(7):1087-97. ">D'Haens 2006</a> was headache. Other less frequent AEs included diarrhea, nausea and abdominal pain. AEs for <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>, which included two different dose groups for once‐daily MMX mesalamine (2.4 g/day and 4.8 g/day), an Asacol reference arm and a placebo group, are reported above (<a href="./references#CD000543-fig-0039" title="">Analysis 5.3</a>. </p> </section> <section id="CD000543-sec-0092"> <h5 class="title">Serious adverse events</h5> <p>Two studies (336 participants) reported on the proportion of participants who experienced at least one SAE (<a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>). No differences in SAE rates were found across any of the dosing subgroups: Salofalk 4.5 g versus 3 g/day (RR 0.50, 95% CI 0.05 to 5.48; 213 participants); Pentasa 4 g versus 2.25 g/day (RR 5.25, 95% CI 0.26 to 107.07; 123 participants; <a href="./references#CD000543-fig-0040" title="">Analysis 5.4</a>). SAEs include aggravation of nasopharyngitis and UC aggravation. </p> </section> <section id="CD000543-sec-0093"> <h5 class="title">Withdrawal due to adverse events</h5> <p>Five dose‐ranging studies (1178 participants) reported the proportion of participants who were withdrawn due to AEs (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>). No differences in rates of withdrawal due to AEs were found in any of the dosing subgroups: Asacol 4.8 g/day versus 2.4 g/day (RR 0.93, 95% CI 0.24 to 3.63; 268 participants); Asacol 4.8 g/day versus 1.6 g/day (RR 0.29, 95% CI 0.02 to 4.26; 49 participants); Asacol 2.4 g/day versus 1.6 g/day (RR 5.00, 95% 0.25 to 101.73; 106 participants); Salofalk 4.5 g/day versus 3 g/day (RR 1.30, 95% CI 0.50 to 3.36; 213 participants); Salofalk 4.5 g/day versus 1.5 g/day (RR 0.80, 95% 0.34 to 1.84; 209 participants); Salofalk 3 g/day versus 1.5 g/day (RR 0.61, 95% CI 0.25 to 1.52; 210 participants); and Pentasa 4 g/day versus 2.25 g/day (RR 0.21, 95% CI 0.01 to 4.28; 123 participants; <a href="./references#CD000543-fig-0041" title="">Analysis 5.5</a>). The common AEs leading to withdrawal included UC aggravation, dizziness and headaches. </p> </section> <section id="CD000543-sec-0094"> <h5 class="title">Withdrawal or exclusions following study entry</h5> <p>Six dose‐ranging studies (1442 participants) reported the proportion of participants who were excluded or withdrawn after entry (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>; <a href="./references#CD000543-bbs2-0034" title="MiglioliM , Bianchi PorroG , BrunettiG , SturnioloGC , and the Italian IBD group. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. European Journal of Gastroenterology and Hepatology1990;2:229-34. MiglioliM , BrunettiG , SturnioloGC , Bianchi PorroG , CampieriM , CottoneM , et al. Oral 5-ASA (Asacol) in mild ulcerative colitis. a randomized double blind dose ranging trial. Italian Journal of Gastroenterology1989;21(1 Suppl):7-8. ">Miglioli 1990</a>; <a href="./references#CD000543-bbs2-0049" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625-9. ">Schroeder 1987</a>; <a href="./references#CD000543-bbs2-0050" title="SninskyCA , CortDH , ShanahanF , PowersBJ , SessionsJT , PruittRE , et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Annals of Internal Medicine1991;115(5):350-5. ">Sninsky 1991</a>). We found a difference between Salofalk 3 g/day and 1.5 g/day (RR 0.61, 95% CI 0.38 to 0.99; 210 participants) and between Salofalk 4.5 g/day and 1.5 g/day (RR 0.62, 95% CI 0.38 to 0.99; 209 participants). However, no other differences were found in rates of exclusions or withdrawals after entry in other dosing subgroups: Asacol 4.8 g/day versus 2.4 g/day (RR 0.68, 95% CI 0.40 to 1.16; 386 participants); Asacol 4.8 g/day versus 1.6 g/day (RR 0.19, 95% CI 0.04 to 1.01; 49 participants); Asacol 3.6 g/day versus 2.4 g/day (RR 0.50, 95% CI 0.10 to 2.48; 48 participants); Asacol 3.6 g/day versus 1.2 g/day (RR 0.42, 95% CI 0.09 to 1.95; 49 participants); Asacol 2.4 g/day versus 1.6 or 1.2 g/day (RR 1.07, 95% CI 0.60 to 1.92; 155 participants); Salofalk 4.5 g/day versus 3 g/day (RR 1.01, 95% CI 0.59 to 1.74; 213 participants); and Pentasa 4 g/day versus 2.25 g/day (RR 0.53, 95% CI 0.24 to 1.14; 123 participants; <a href="./references#CD000543-fig-0042" title="">Analysis 5.6</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000543-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000543-sec-0095"></div> <section id="CD000543-sec-0096"> <h3 class="title" id="CD000543-sec-0096">Summary of main results</h3> <p>This systematic review largely confirms the results of previous meta‐analyses (<a href="./references#CD000543-bbs2-0136" title="FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub3]">Feagan 2012</a>; <a href="./references#CD000543-bbs2-0137" title="SutherlandLR , MayGR , ShafferEA . Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine1993;118:540-9.">Sutherland 1993</a>; <a href="./references#CD000543-bbs2-0138" title="SutherlandLR , RothDE , BeckPL . Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases1997;3:65-78.">Sutherland 1997</a>; <a href="./references#CD000543-bbs2-0139" title="SutherlandLR , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub2]">Sutherland 2006b</a>; <a href="./references#CD000543-bbs2-0140" title="WangY , ParkerCE , BhanjiT , FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD000543. [DOI: 10.1002/14651858.CD000543.pub4]">Wang 2016</a>), but differs from the previous work in a variety of ways. This update identified one new included study (<a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a>) and one ongoing study (<a href="./references#CD000543-bbs2-0076" title="NCT02522767. Mesalamine 4 g sachet for the induction of remission in active, mild to moderate ulcerative colitis (UC) (Ferring Pharmaceuticals). clinicaltrials.gov/show/NCT02522767 (first received 13 August 2015). ">NCT02522767</a>), and therefore now includes 54 studies with 9612 participants. <a href="./references#CD000543-bbs2-0005" title="D'HaensGR , SandbornWJ , ZouG , StittLW , RutgeertsPJ , GilgenD , et al. Randomised non-inferiority trial: 1600mg versus 400mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2017;46(3):292-302. ">D'Haens 2017</a> is a dosing study and assessed 3.2 g of oral mesalazine administered as two 1600 mg tablets taken once daily or four 400 mg tablets taken twice daily. <a href="./references#CD000543-bbs2-0076" title="NCT02522767. Mesalamine 4 g sachet for the induction of remission in active, mild to moderate ulcerative colitis (UC) (Ferring Pharmaceuticals). clinicaltrials.gov/show/NCT02522767 (first received 13 August 2015). ">NCT02522767</a> is an ongoing study assessing 4 g extended‐release granules of mesalamine and placebo. We have also added serious adverse events (SAEs) as a new secondary outcome in this version of this review. </p> <p>The effectiveness of oral 5‐ASA preparations for the treatment of mild‐to‐moderate active UC was confirmed. Oral 5‐ASA is superior to placebo for induction of remission and clinical improvement in participants with active mild‐to‐moderate UC. The number needed to treat for an additional beneficial outcome from treatment is nine patients. </p> <p>As we found in our previous meta‐analysis, there was a trend in favor of a slight benefit for the newer 5‐ASA preparations over SASP for the induction of global/clinical and endoscopic improvement (including remission). There are several points to be considered. It is possible that larger sample populations would confirm this finding, but the clinical relevance of such a difference would be debatable. Another possible explanation for the difference may be related to our use of the ITT principle, which should benefit medications with lower dropout rates, in this case 5‐ASA. </p> <p>The assumption that SASP serves only as a pro‐drug to deliver 5‐ASA to its site of action has been questioned in light of the observation that increasing doses of 5‐ASA, within the dose‐response range of SASP, fail to enhance its efficacy beyond that of the standard 2 to 4 g therapeutic doses of SASP (<a href="./references#CD000543-bbs2-0096" title="HayllarJ , BjarnasonI . Sulphasalazine in ulcerative colitis: In memoriam?Gut1991;32(5):462-3.">Hayllar 1991</a>). In active disease, a variety of 5‐ASA to SASP mass ratios were studied; doses of 5‐ASA corresponding to up to 10 g of SASP were commonly prescribed while just 2 to 4 g/day of SASP were used as controls. Despite this discrepancy, we could not confirm a significant superiority of 5‐ASA. Furthermore, when trial arms were subdivided according to their 5‐ASA/SASP mass ratios, r (r &lt; 1/2, 1/1 &gt; r ≥ 1/2, r ≥ 1/1), no general dose trends could be detected (data not shown). It has been suggested that if an increase in the colonic concentration of 5‐ASA within the range of SASP dose‐dependence does not parallel an enhanced efficacy, then 5‐ASA is unlikely to be the only mediator of therapeutic activity (<a href="./references#CD000543-bbs2-0096" title="HayllarJ , BjarnasonI . Sulphasalazine in ulcerative colitis: In memoriam?Gut1991;32(5):462-3.">Hayllar 1991</a>). Elucidation of the mechanisms of action of 5‐ASA, sulfapyridine, and SASP (reviewed by <a href="./references#CD000543-bbs2-0093" title="GreenfieldSM , PunchardNA , TeareJP , ThompsonRP . Review article: The mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology &amp; Therapeutics1993;7(4):369-83.">Greenfield 1993</a>), corroborated by their individual clinical effects, may explain this curious finding, as well as facilitate the determination of the currently unknown etiology of UC. </p> <p>It was apparent that the newer 5‐ASA preparations were not entirely free of causing adverse effects in a number of participants. However, the incidence of AEs, SAEs and withdrawals due to the 5‐ASA formulations did not significantly differ from that associated with placebo. Furthermore, there were significantly more withdrawals due to AEs with SASP than with 5‐ASA. </p> <p>Olsalazine caused a significantly higher proportion of withdrawals due to AEs relative to placebo, but lower than the proportion caused by SASP. The most common AE attributed to Olsalazine was diarrhea, an effect previously observed in approximately 10% of participants receiving the drug (<a href="./references#CD000543-bbs2-0099" title="IrelandA , JewellDP . Olsalazine in patients intolerant of sulphasalazine. Scandinavian Journal of Gastroenterology1987;22(9):1038-40.">Ireland 1987</a>). It should be noted that there may have been a bias in favor of SASP, since many of the studies involved participants who were known to have tolerated SASP in the past. It has been suggested that protocol alterations may reduce the withdrawal rates in future trials, since encouraging participants to take Olsalazine with meals appears to reduce the incidence of diarrhea to approximately 3% of participants (<a href="./references#CD000543-bbs2-0100" title="JärnerotG . Withdrawal rates because of diarrhea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose-titrated. Gastroenterology1996;110:A932.">Jarnerot 1996</a>); of the included Olsalazine trials, only two reported that participants were instructed to take their medication with meals (<a href="./references#CD000543-bbs2-0021" title="HetzelDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , HeckerR , et al. Azodisacylate (ADS) in the treatment of ulcerative colitis (UC): a controlled trial and assessment of drug disposition. Gastroenterology1985;88:A1418. HetzelDJ , ShearmanDJ , BochnerF , ImhoffDM , GibsonGE , FitchRJ , et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology1986;1:257-66. HetzelDJ , ShearmanDJ , LabrooyJ , BochnerF , ImhoffDM , GibsonGE , et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scandinavian Journal of Gastroenterology Supplement1988;23(148):61-9. ">Hetzel 1986</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>). Mesalamine‐induced interstitial nephritis is a serious but rare AE (<a href="./references#CD000543-bbs2-0089" title="ElseviersMM , D'HaensG , LereboursE , PlaneC , StolearJC , RieglerG , et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?Clinical Nephrology2004;61(2):83-9.">Elseviers 2004</a>). Although there have been case reports of interstitial nephritis in people with IBD treated with 5‐ASA (<a href="./references#CD000543-bbs2-0078" title="ArendLJ , SpringateJE . Interstitial nephritis from mesalazine: case report and literature review. Pediatric Nephrology2004;19(5):550-3.">Arend 2004</a>; <a href="./references#CD000543-bbs2-0092" title="FrandsenNE , SaugmannS , MarcussenN . Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron2002;92(1):200-2.">Frandsen 2002</a>; <a href="./references#CD000543-bbs2-0109" title="MaedaS , NomuraS , TaharaM , HanedaM , KikkawaR . Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis. Nihon Naika Gakkai Zasshi2001;90(5):872-3.">Maeda 2001</a>), there were no reports of interstitial nephritis in the studies included in this systematic review. </p> <p>This meta‐analysis indicates that oral 5‐ASA administered once daily is as effective as conventional dosing (twice or three times daily) for induction therapy in mild to moderately‐active UC. High‐certainty evidence suggests no difference between once‐daily and conventional dosing for induction of remission, and moderate‐certainty evidence suggests no differences in clinical improvement. Furthermore, subgroup analyses by drug formulation (MMX mesalazine, Salofalk, Asacol and Pentasa) showed no differences in efficacy between once‐daily and conventional dosing for induction of remission. However, the latter results should be interpreted cautiously since only five formulations were evaluated in this analysis. </p> <p>We found no differences between once‐daily and conventionally‐dosed oral 5‐ASA for safety outcomes, including the overall incidence of AEs, SAEs, withdrawal from treatment due to an AE or exclusions or withdrawals after entry. In keeping with the well‐established safety profile of oral 5‐ASA, most of the AEs reported in the studies were mild‐to‐moderate in intensity. Common AEs were gastrointestinal symptoms (e.g. flatulence, abdominal pain, nausea, and diarrhea), headache and worsening UC. </p> <p>Important patient preference and adherence differences may exist between dosing regimens. In the study that measured participant preference, most preferred once‐daily dosing to conventional dosing (<a href="./references#CD000543-bbs2-0028" title="KruisW , GorelovA , KiudelisG , RáczI , PokrotnieksJ , HorynskiM , et al. Once daily dosing of 3g mesalamine (Salofalk® Granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology2007;132(4 Suppl 1):A130-1. KruisW , KiudelisG , RáczI , GorelovIA , PokrotnieksJ , HorynskiM , et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut2009;58(2):233-40. ">Kruis 2009</a>). Although it is generally believed that administration of fewer tablets and less frequent dosing improves both efficacy and adherence, we could not demonstrate the superiority of once‐daily dosing for either of these outcomes. This result suggests that patient adherence may not be enhanced by once‐daily dosing in the clinical trial setting. Several possible explanations exist for these observations, but the most plausible one concerns the unique aspects of the clinical trial environment. It is noteworthy that adherence was remarkably high in the studies that measured this outcome (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>; <a href="./references#CD000543-bbs2-0030" title="LichtensteinGR , KammMA , BodduP , GubergritsN , LyneA , ButlerT , et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology2007;5(1):95-102. ">Lichtenstein 2007</a>). The pooled adherence rate was 92% in the once‐daily dosing group compared to 94% in the conventional‐dosing group. These rates likely reflect the highly supervised environment in which the studies were conducted. Adherence to medication in clinical trials is generally greater than in clinical practice, since participants are highly selected volunteers who are more likely, in general, to adhere to drug regimens (<a href="./references#CD000543-bbs2-0077" title="AndradeSE , WalkerAM , GottliebLK , HollenbergNK , TestaMA , SaperiaGM , et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings?New England Journal of Medicine1995;332(17):1125-31.">Andrade 1995</a>; <a href="./references#CD000543-bbs2-0101" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000543-bbs2-0104" title="KaneSV . Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2006;23(5):577-85.">Kane 2006</a>; <a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>). In addition, adherence is continuously reinforced during the clinical trial process. Thus, it may be difficult to detect differences in adherence between once‐daily and multiple‐dose regimens in this setting. Accordingly, there is a need to compare dosing regimens in large‐scale community‐based studies.Reported adherence rates in community‐based studies range from 40% to 60% and are especially poor among people in remission (<a href="./references#CD000543-bbs2-0101" title="KaneSV , CohenRD , AikensJE , HanauerSB . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology2001;96(10):2929-33.">Kane 2001</a>; <a href="./references#CD000543-bbs2-0102" title="KaneS , HuoD , AikensJ , HanauerS . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine2003;114(1):39-43.">Kane 2003a</a>; <a href="./references#CD000543-bbs2-0107" title="LevyRL , FeldAD . Increasing patient adherence to gastroenterology treatment and prevention regimens. American Journal of Gastroenterology1999;94(7):1733-42.">Levy 1999</a>; <a href="./references#CD000543-bbs2-0127" title="ShaleMJ , RileySA . Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology &amp; Therapeutics2003;18(2):191-8.">Shale 2003</a>). However, whether once‐daily dosing regimens improve adherence in the community remains unknown. </p> <p>Experience from other indications suggests that factors other than the dosing regimen are important for long‐term compliance (<a href="./references#CD000543-bbs2-0081" title="BrixnerD , MagowanS , AccorttN . Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. In: Academy of Managed Care Pharmacy Annual Meeting. San Diego, CA, 2007.">Brixner 2007</a>; <a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>). Long‐term observations in people with UC as well as in other indications indicate that patients' and physicians' behaviors play a dominant role in adherence (<a href="./references#CD000543-bbs2-0080" title="BeaulieuDB , SchwartzDA . Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes. Medscape CME Gastroenterology 2009. Available from www.medscape.org/viewarticle/713895.">Beaulieu 2009</a>; <a href="./references#CD000543-bbs2-0110" title="MagowanS , KaneS , LangeJL . 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. American Journal of Gastroenterology2006;101:S447. Abstract 1144.">Magowan 2006</a>). The patient‐physician relationship should reinforce adherence through education, open communication and mutual agreement about the value of treatment (<a href="./references#CD000543-bbs2-0105" title="KaneSV , BrixnerD , RubinDT , SewitchMJ . The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy2008;14(1 Suppl A):S2-12.">Kane 2008</a>). </p> <p>Moderate‐certainty evidence suggests that there may be little or no difference in efficacy or safety between the various formulations of oral 5‐ASA. To further support the conclusion that there is no difference in efficacy between 5‐ASA formulations, it should be noted that only one induction study reported a difference in efficacy between two different formulations of 5‐ASA (<a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a>). <a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a> reported that Balsalazide 6.75 g/day was superior to Asacol 2.4 g/day for induction of complete remission (none or mild symptoms and sigmoidoscopy score of 0 or 1 at 12 weeks). However, two similar trials did not support these findings (<a href="./references#CD000543-bbs2-0029" title="LevineDS , PruittR , RiffD , KovalG , SalesD , WrubleL , et al. A multi-center, double-blind dose-response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology1997;112:A1026. LevineDS , RiffDS , PruittR , WrubleL , KovalG , SalesD , et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(6):1398-407. ">Levine 2002</a>; <a href="./references#CD000543-bbs2-0038" title="PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJ , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology2002;97(12):3078-86. PruittR , HansonJ , SafdiM , WrubleL , HardiR , JohansonJF , et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A120-1. PruittRE , RosenAA , WrubleLD , SedghiS , ShepardRD , MareyaSM . Safety and tolerability of twice-daily balsalazide tablets: Results from 2 randomized, double-blind, multicenter, phase 3 studies and 1 open-label, multicenter, phase 3 study. Gastroenterology2009;136(5 Suppl 1):A523. ">Pruitt 2002</a>). </p> <p>Pharmacokinetic studies suggest that systemic exposure to 5‐ASA is similar for all oral 5‐ASA formulations and 5‐ASA pro‐drugs (<a href="./references#CD000543-bbs2-0121" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>; <a href="./references#CD000543-bbs2-0122" title="SandbornWJ , HanauerSB , BuchA . Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal. American Journal of Gastroenterology2002;97:S263.">Sandborn 2002b</a>; <a href="./references#CD000543-bbs2-0123" title="SandbornWJ , HanauerSB . The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review. American Journal of Gastroenterology2002;97:S269.">Sandborn 2002c</a>; <a href="./references#CD000543-bbs2-0124" title="SandbornWJ , HanauerSB . Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2003;17(1):29-42.">Sandborn 2003</a>). With the exception of Olsalazine‐related diarrhea (<a href="./references#CD000543-bbs2-0009" title="FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double-blind trial. Gut1989;30(10):1354-61. FeurleGE , TheuerD , VelascoS , BarryBA , WordehoffD , SommerA , et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gastroenterology1988;94(5 Part 2):A126. ">Feurle 1989</a>; <a href="./references#CD000543-bbs2-0018" title="HanauerSB , BarishC , PambiancoD , SigmonR , GannanR , KovalG , et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology1996;110:A921. ">Hanauer 1996</a>; <a href="./references#CD000543-bbs2-0045" title="RobinsonM , GitnickG , BalartL , DasK , TurkinD . Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology1988;84:A381. RobinsonM , HanauerS , HoopR , ZbrozekA , WilkinsonC . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics1994;8(1):27-34. ">Robinson 1994</a>; <a href="./references#CD000543-bbs2-0054" title="ZinbergJ , MolinasS , DasKM . A double-blinded, placebo-controlled clinical study of azodisalicylate sodium (olsalazine) in the treatment of ulcerative colitis. Gastroenterology1987;92:A1711. ZinbergJ , MolinasS , DasKM . Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. American Journal of Gastroenterology1990;85(5):562-6. ">Zinberg 1990</a>), there does not appear to be any difference in safety between the various formulations of oral 5‐ASA. The overall pooled risk ratios showed no differences in the incidence of AEs, SAEs, withdrawal due to AEs or exclusions or withdrawals after entry. Thus, all of the 5‐ASA formulations can be considered safe and effective for the treatment of active UC, and from a practical standpoint they can be considered therapeutically equivalent at equimolar doses (<a href="./references#CD000543-bbs2-0121" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>). Treatment with sulfasalazine and Olsalazine may not be preferable due to the high frequency of AEs. When selecting among the remaining 5‐ASA formulations, physicians and patients should consider dose‐response data for 5‐ASA doses up to 4 to 4.8 g/day of 5‐ASA, adherence issues related to dose forms (size of dose form and total number of tablets or capsules per day), and price, when deciding which formulations to use (<a href="./references#CD000543-bbs2-0121" title="SandbornWJ . Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology2002;97(12):2939-41.">Sandborn 2002a</a>). </p> <p>The ASCEND I, ASCEND II and ASCEND III studies compared Asacol 4.8 g/day to Asacol 2.4 g/day in people with mild to moderately‐active UC (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>), or in people with moderately‐active disease (<a href="./references#CD000543-bbs2-0046" title="SandbornWJ , RegulaJ , FeaganB , BelousovaEA , JojicNV , LukasM , et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology2008;134(4 Suppl 1):A99. SandbornWJ , RegulaJ , FeaganBG , BelousovaE , JojicN , LukasM , et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology2009;137(6):1934-43. ">Sandborn 2009</a>). A pooled analysis of the three studies (1459 participants) showed no difference between the dose groups in failure to induce clinical improvement. However, subgroup analyses indicated that participants with moderate disease may benefit from the higher dose of 4.8 g/day (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>), particularly among participants previously treated with corticosteroids, oral 5‐ASA, rectal therapies or multiple UC medications (<a href="./references#CD000543-bbs2-0019" title="HanauerSB , SandbornWJ , KornbluthA , KatzS , SafdiM , WoogenS , et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology2005;100(11):2478-85. ">Hanauer 2005</a>; <a href="./references#CD000543-bbs2-0020" title="HanauerSB , SandbornWJ , DallaireC , ArchambaultA , YacyshynB , YehC , et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology2007;21(12):827-34. ">Hanauer 2007</a>; <a href="./references#CD000543-bbs2-0046" title="SandbornWJ , RegulaJ , FeaganB , BelousovaEA , JojicNV , LukasM , et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/d (800mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology2008;134(4 Suppl 1):A99. SandbornWJ , RegulaJ , FeaganBG , BelousovaE , JojicN , LukasM , et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology2009;137(6):1934-43. ">Sandborn 2009</a>). Both doses appear to have similar efficacy in participants with mild disease, which suggests that a dose of 2.4 g/day may be preferred for people with mildly‐active disease. <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a> compared Pentasa 4 g/day to Pentasa 2.25 g/day in people with moderate disease and found a difference in favor of the higher‐dose group for clinical improvement which appears to confirm the results of the ASCEND studies. <a href="./references#CD000543-bbs2-0022" title="HiwatashiN , SuzukiY , MitsuyamaK , MunakataA , HibiT . Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology2011;46(1):46-56. ">Hiwatashi 2011</a> concluded that people with severe symptoms such as relapse‐remitting and moderately‐active disease should be treated initially with 4 g/day. </p> <p>A pooled analysis of two studies (194 participants) comparing MMX mesalazine 4.8 g to 2.4 g day did not show a difference between the dose groups in failure to induce clinical remission or improvement, suggesting that both dosage groups are efficacious in people with mild to moderately‐active UC (<a href="./references#CD000543-bbs2-0004" title="D'HaensG , HommesD , EngelsL , BaertF , Van der WaaijL , ConnorP , et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacology and Therapeutics2006;24(7):1087-97. ">D'Haens 2006</a>; <a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>). A subgroup analysis by severity did not show any advantage for the higher dose (4.8 g/day) in participants with moderate disease (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>). However, further research may be necessary to identify those who will benefit from varying doses of MMX mesalamine (<a href="./references#CD000543-bbs2-0025" title="HanauerS , SandbornW , LichtensteinG , KammM , BarrettK , JosephR . MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflammatory Bowel Diseases2007;13(S5):663. KammMA , SandbornWJ , GassullM , SchreiberS , JackowskiL , ButlerT , et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology2007;132(1):66-75. ">Kamm 2007</a>). <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a> evaluated the efficacy of three doses of Salofalk mesalamine pellets (1.5, 3.0, and 4.5 g/day) in people with active UC, and found no difference in remission rates between 4.5 g/day and 3 g/day, and a difference in remission rates between 3 g and 1.5 g/day. <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a> concluded that there was no dose response between the three dose groups and recommended the lowest effective dose (1.5 g/day) for treatment of people with mild‐to‐moderate UC. People failing at this dose might benefit from an increase to 3 g/day, but doses higher than this amount do not appear to provide any additional benefit (<a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>). </p> </section> <section id="CD000543-sec-0097"> <h3 class="title" id="CD000543-sec-0097">Overall completeness and applicability of evidence</h3> <p>We believe the evidence from this review is applicable to most people with mild‐to‐moderate ulcerative colitis. The evidence assesses 5‐ASA compared with placebo, sulfasalazine and comparator 5‐ASA. The studies also assess 5‐ASA dose‐ranging studies and once‐daily dosing studies compared to conventional‐dosing studies. All the safety and efficacy outcomes which we aimed to report on were included in the studies, but there were a couple of outcomes that were rarely reported, including failure to adhere to the medication regimen and endoscopic remission. The review found mainly moderate‐to‐high‐certainty evidence for the oral 5‐ASA versus placebo and oral 5‐ASA versus SASP studies, which might therefore imply that this area does not require additional studies. However, the evidence comparing oral 5‐ASA with comparator 5‐ASA is mostly of moderate certainty, and once‐daily with conventional dosing is mostly low‐to‐moderate‐certainty evidence. Additional studies for these comparisons may therefore change the overall results. </p> </section> <section id="CD000543-sec-0098"> <h3 class="title" id="CD000543-sec-0098">Quality of the evidence</h3> <p>We assessed the included studies using the Cochrane 'Risk of bias' tool and GRADE criteria. Five studies were rated at high risk of bias due to incomplete outcome data (<a href="./references#CD000543-bbs2-0015" title="GreenJR , HoldsworthCD , LoboAJ , LeicesterR , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis. In: Digestive Disease Week Abstract Book. 1997. GreenJR , LoboAJ , HoldsworthCD , LeicesterRJ , GibsonJA , KerrGD , et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. Gastroenterology1998;114(1):15-22. ">Green 1998</a>; <a href="./references#CD000543-bbs2-0027" title="KruisW , Bar-MeirS , FeherJ , MickischO , MlitzH , FaszczykM , et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology2003;1(1):36-43. KruisW , MeirSB , FeherJ , StolteM . Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology2000;118(4 Suppl 2):A780. ">Kruis 2003</a>) and lack of blinding (<a href="./references#CD000543-bbs2-0007" title="FarupPG , HinterleitnerTA , LukásM , HébuterneX , RachmilewitzD , CampieriM , et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases2001;7(3):237-42. FarupPG , OddssonE , HinterleitnerT . Mesalamine 4 g prolonged release granules BID and QID versus tablets QID for mild/moderate UC. Gastroenterology1999;116(4 Part 2):A713. ">Farup 2001</a>; <a href="./references#CD000543-bbs2-0011" title="FlouriéB , HagègeH , TucatG , MaetzD , HébuterneX , KuyvenhovenJP , et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2013;37(8):767-75. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82. FlouriéB , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology2012;142(5 suppl 1):S197. FlouriéB , KuyvenhovenJ , ProbertC , DewitO . Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population. Journal of Crohn's &amp; Colitis2013;7:S236. PierikM , HagègeH , TucatG , MascleeA , DewitO , ProbertC , et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Journal of Crohn's &amp; Colitis2012;6:S82-3. ">Flourié 2013</a>; <a href="./references#CD000543-bbs2-0052" title="TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , EliseiW . Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Gastroenterology2005;128((4 Suppl 2)):A17. TursiA , BrandimarteG , GiorgettiGM , FortiG , ModeoME , GigliobiancoA . Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical Science Monitor2004;10(11):126-31. ">Tursi 2004</a>). Thirty‐two of 54 included studies did not describe the method used for randomization and were rated as unclear for this domain. Twenty‐six studies did not describe methods used for allocation concealment and were rated as unclear for this domain. The methods used for blinding were not described in five studies, and we rated these studies as unclear. Twenty studies were rated as unclear for incomplete outcome data because reasons for withdrawal were either not described or were not attributed to intervention groups. Six studies were rated as unclear for selective reporting. </p> <p>For the oral 5‐ASA versus placebo comparison clinical remission and AEs were rated as high certainty. The outcomes clinical improvement, endoscopic remission and withdrawal due to AEs were rated as moderate, due to heterogeneity and sparse data, and SAEs were rated as low certainty due to very sparse data (<a href="./full#CD000543-tbl-0001">summary of findings Table 1</a>). For the 5‐ASA versus SASP studies the outcomes induction of remission and clinical improvement were rated as moderate certainty (due to sparse data) and high certainty respectively. The AEs and withdrawal due to AE outcomes were both rated as moderate, due to sparse data, and SAEs were low‐certainty due to very sparse data (<a href="./full#CD000543-tbl-0002">summary of findings Table 2</a>). For the once‐daily compared to conventional‐dosing studies, the overall certainty of the evidence using the GRADE approach was rated as high for the primary outcome (clinical remission) and moderate for the secondary outcomes of clinical improvement and AEs, due to sparse data (<a href="./full#CD000543-tbl-0003">summary of findings Table 3</a>). The studies comparing the various formulations of 5‐ASA indicated that the overall certainty of the evidence for the primary outcome (failure to induce complete global or clinical remission) was moderate, due to a high risk of bias (lack of blinding) in two studies in the pooled analysis (See <a href="./full#CD000543-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD000543-sec-0099"> <h3 class="title" id="CD000543-sec-0099">Potential biases in the review process</h3> <p>A comprehensive literature search helped minimize bias in relation to study selection. In addition two review authors independently screened the studies, extracted the data and assessed the risks of bias. There were limitations to drawing general conclusions. Almost every study used a unique clinical or endoscopic index. Unlike Crohn's disease, the lack of standard indices in UC prevented the collection of consistent treatment efficacy data and makes comparisons across clinical studies difficult. The use of endoscopic remission as an outcome would provide a more rigorous assessment of treatment efficacy in clinical trials. Clinicians should use a standardized approach to assess endoscopic appearance to allow for comparisons across trials. Most of the included studies were not of sufficient duration to permit documentation of endoscopic healing. Results were also periodically obscured in several studies that failed to specify the treatment arm to which certain excluded participants were initially randomized. Despite these and other common factors that must be considered when interpreting meta‐analyses, the data provided strong evidence that pointed towards a number of conclusions. </p> </section> <section id="CD000543-sec-0100"> <h3 class="title" id="CD000543-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>We have identified two other systematic reviews that have assessed 5‐ASA for the induction of remission in UC (<a href="./references#CD000543-bbs2-0091" title="FordAC , AchkarJP , KhanKJ , KaneSV , TalleyNJ , MarshallJK , et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology2011;106(4):601-16.">Ford 2011</a>; <a href="./references#CD000543-bbs2-0103" title="KaneSV , BjorkmanDJ . The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: A systematic review. Reviews in Gastroenterological Disorders2003;3:210.">Kane 2003b</a>). <a href="./references#CD000543-bbs2-0091" title="FordAC , AchkarJP , KhanKJ , KaneSV , TalleyNJ , MarshallJK , et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology2011;106(4):601-16.">Ford 2011</a> is a systematic review and meta‐analysis assessing the efficacy of 5‐ASA in people with UC. The review included 37 RCTs with 19 induction studies (nine studies comparing 5‐ASA to placebo and 10 studies comparing different doses of 5‐ASA) and 18 maintenance studies. This review concluded that 5‐ASAs are highly effective for both the induction of remission and prevention of relapse in UC participants. </p> <p><a href="./references#CD000543-bbs2-0103" title="KaneSV , BjorkmanDJ . The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: A systematic review. Reviews in Gastroenterological Disorders2003;3:210.">Kane 2003b</a> is a systematic review on the efficacy of oral 5‐ASA for active UC. Thirty‐one studies were identified and 19 met the inclusion criteria. This review suggested that mesalamine is superior to placebo for treating active UC and that 5‐ASA products appear to be as effective as sulfasalazine, but available data do not suggest a difference in efficacy between any of the 5‐ASA preparations. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000543-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000543-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000543-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 1: Failure to induce global/clinical remission" data-id="CD000543-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 1: Failure to induce global/clinical remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 2: Failure to induce global/clinical improvement (including remission)" data-id="CD000543-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 2: Failure to induce global/clinical improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 3: Failure to induce endoscopic remission" data-id="CD000543-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 3: Failure to induce endoscopic remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 4: Failure to induce endoscopic improvement (including remission)" data-id="CD000543-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 4: Failure to induce endoscopic improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 5: Adverse events" data-id="CD000543-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 5: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 6: Serious adverse events" data-id="CD000543-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 6: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 7: Withdrawals due to adverse events" data-id="CD000543-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 7: Withdrawals due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 5‐ASA versus placebo, Outcome 8: Exclusions and withdrawals after study entry" data-id="CD000543-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: 5‐ASA versus placebo, Outcome 8: Exclusions and withdrawals after study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 1: Failure to induce global/clinical remission" data-id="CD000543-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 1: Failure to induce global/clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 2: Failure to induce global/clinical improvement (including remission)" data-id="CD000543-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 2: Failure to induce global/clinical improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 3: Failure to induce endoscopic improvement (including remission)" data-id="CD000543-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 3: Failure to induce endoscopic improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 4: Adverse events" data-id="CD000543-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 4: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 5: Serious adverse events" data-id="CD000543-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 5: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 6: Withdrawals due to adverse events" data-id="CD000543-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 6: Withdrawals due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: 5‐ASA versus sulfasalazine, Outcome 7: Exclusions and withdrawals after study entry" data-id="CD000543-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: 5‐ASA versus sulfasalazine, Outcome 7: Exclusions and withdrawals after study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 1: Failure to induce global/clinical remission" data-id="CD000543-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 1: Failure to induce global/clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 2: Failure to induce global/clinical improvement (including remission)" data-id="CD000543-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 2: Failure to induce global/clinical improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 3: Failure to induce global/clinical improvement (sensitivity analysis)" data-id="CD000543-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 3: Failure to induce global/clinical improvement (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 4: Failure to induce endoscopic remission" data-id="CD000543-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 4: Failure to induce endoscopic remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 5: Failure to induce endoscopic improvement (including remission)" data-id="CD000543-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 5: Failure to induce endoscopic improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 6: Failure to adhere to medication regimen" data-id="CD000543-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 6: Failure to adhere to medication regimen </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 7: Compliance" data-id="CD000543-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 7: Compliance</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 8: Adverse events" data-id="CD000543-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 8: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 9: Serious adverse events" data-id="CD000543-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 9: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 10: Withdrawals due to adverse events" data-id="CD000543-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 10: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Once daily dosing versus conventional dosing, Outcome 11: Exclusions and withdrawals after study entry" data-id="CD000543-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Once daily dosing versus conventional dosing, Outcome 11: Exclusions and withdrawals after study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 1: Failure to induce global/clinical remission" data-id="CD000543-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 1: Failure to induce global/clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 2: Failure to induce global/clinical remission (sensitivity analysis)" data-id="CD000543-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 2: Failure to induce global/clinical remission (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 3: Failure to induce global/clinical improvement (including remission)" data-id="CD000543-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 3: Failure to induce global/clinical improvement (including remission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 4: Failure to induce global/clinical improvement (sensitivity analysis)" data-id="CD000543-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 4: Failure to induce global/clinical improvement (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 5: Adverse events" data-id="CD000543-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 5: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 6: Serious adverse events" data-id="CD000543-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 6: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 7: Withdrawals due to adverse events" data-id="CD000543-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 7: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 8: Exclusions and withdrawals after study entry" data-id="CD000543-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: 5‐ASA versus comparator 5‐ASA, Outcome 8: Exclusions and withdrawals after study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐ASA dose ranging, Outcome 1: Failure to Induce Global/Clinical Remission" data-id="CD000543-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: 5‐ASA dose ranging, Outcome 1: Failure to Induce Global/Clinical Remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐ASA dose ranging, Outcome 2: Failure to Induce Global/Clinical Remission or Improvement" data-id="CD000543-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: 5‐ASA dose ranging, Outcome 2: Failure to Induce Global/Clinical Remission or Improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐ASA dose ranging, Outcome 3: Development of any adverse event" data-id="CD000543-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: 5‐ASA dose ranging, Outcome 3: Development of any adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐ASA dose ranging, Outcome 4: Serious adverse events" data-id="CD000543-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: 5‐ASA dose ranging, Outcome 4: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐ASA dose ranging, Outcome 5: Withdrawal from study due to adverse event" data-id="CD000543-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: 5‐ASA dose ranging, Outcome 5: Withdrawal from study due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000543-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/urn:x-wiley:14651858:media:CD000543:CD000543-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: 5‐ASA dose ranging, Outcome 6: Exclusions and withdrawals after entry" data-id="CD000543-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_t/tCD000543-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: 5‐ASA dose ranging, Outcome 6: Exclusions and withdrawals after entry</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/media/CDSR/CD000543/image_n/nCD000543-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000543-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral 5‐ASA versus placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral 5‐ASA versus placebo for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Oral 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce complete global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>830 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b><br/>(681 to 739) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/>(0.82 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2387<br/>(11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as a score of 0 points for stool frequency and rectal bleeding </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>651 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b><br/>(397 to 488) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> <br/>(0.61 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2256<br/>(14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as a decrease of 3 points from baseline in the overall modified UC‐DAI score </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> <p>Follow‐up: 6 ‐ 14 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>639 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> </p> <p>(428 to 569)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> </p> <p>(0.67 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1154</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic improvement was defined as endoscopy/sigmoidoscopy score of ≤ 1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome is not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><br/>(413 to 520) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/>(0.85 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1218<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included headache, nausea, abdominal pain or cramps, nasopharyngitis or symptoms of upper respiratory infection, rash. anorexia or loss of appetite, flatulence or gas, gastrointestinal disorders and fever </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1,000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> <p>(4 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> </p> <p>(0.18 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>746</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included aggravation of UC, malaise, abdominal abscess, pancreatitis and an inguinal hernia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 6 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b><br/>(47 to 85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b><br/>(0.54 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2372<br/>(13 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal were not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio <b>UC:</b> ulcerative colitis; <b>UC‐DAI: ulcerative colitis ‐ disease activity index</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to heterogeneity I<sup>2</sup> = 47%.<br/><sup>c</sup>Downgrade one level due to heterogeneity I<sup>2</sup> = 42%.<br/><sup>d</sup>Downgraded two levels due to very sparse data (13 events).<br/><sup>e</sup>Downgraded one level due to sparse data (164 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral 5‐ASA versus placebo for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000543-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral 5‐ASA versus SASP for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral 5‐ASA versus SASP for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Oral 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SASP</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>583 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>525 per 1000</b><br/>(449 to 606) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> <br/>(0.77 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>526<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as the return to stool frequency (2 ‐ 3 stools or fewer a day) without the presence of blood </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b><br/>(355 to 472) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/>(0.76 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1053<br/>(14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as reduction in their clinical activity index</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported this outcome but meta‐analysis not performed as they used different measurement indices. Neither study showed significant differences in complete endoscopic remission between 5‐ASA and SASP </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>287 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b><br/>(103 to 181) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> <br/>(0.36 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>909<br/>(12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included nausea, headache, dyspepsia, vomiting, abdominal pain and rash </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> <p>(11 to 246)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(0.28 to 6.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included erythematous rash, venous thrombosis, carcinoma, acute pancreatitis, rheumatoid arthritis and erythema nodosum </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 4 ‐ 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b><br/>(31 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.40</b> <br/>(0.24 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal included nausea, headaches and rashes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to sparse data (294 events).<br/><sup>c</sup>Downgraded one level due to sparse data (190 events).<br/><sup>d</sup>Downgraded two levels due to very sparse data (5 events).<br/><sup>e</sup>Downgraded one level due to sparse data (54 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral 5‐ASA versus SASP for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000543-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Once daily dosing versus conventional dosing for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Once‐daily dosing versus conventional dosing for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Once‐daily dosing </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Conventional dosing</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Once daily dosing</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>611 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>605 per 1000</b><br/>(569 to 648) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.93 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1761<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as UC‐DAI score of ≤ 1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/>(180 to 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/>(0.49 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as decrease of ≤ 3 points from baseline in the total modified UC‐DAI score </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>892 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>910 per 1000</b><br/>(180 to 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.98 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>817<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic remission was defined as Mayo Clinic Endoscopic Subscale subscore of 0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b><br/>(39 to 176) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> <br/>(0.64 to 2.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence to medication regimen was defined as compliance with taking medications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>318 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b><br/>(283 to 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.89 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1586<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included flatulence, abdominal pain, nausea, diarrhea, nasopharyngitis, dyspepsia, headache and worsening of ulcerative colitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> <p>(12 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b> </p> <p>(0.68 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1586</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included pancreatitis, hepatitis, polyuria, chromaturia, upper respiratory tract infection and measles </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b><br/>(18 to 49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.54 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1757<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal were not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio; <b>UC:</b> ulcerative colitis; <b>UC‐DAI: ulcerative colitis ‐ disease activity index</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to sparse data (153 events).<br/><sup>c</sup>Downgraded two levels due to very sparse data (26 events).<br/><sup>d</sup>Downgraded one level due to sparse data (271 events).<br/><sup>e</sup>Downgraded two levels due to very sparse data (33 events).<br/><sup>f</sup>Downgraded two levels due to very sparse data (9 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Once daily dosing versus conventional dosing for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000543-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral 5‐ASA versus comparator 5‐ASA for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Oral 5‐ASA versus comparator 5‐ASA for induction of remission in ulcerative colitis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with active mild‐to‐moderate ulcerative colitis<br/><b>Settings:</b> Outpatient<br/><b>Intervention:</b> Oral 5‐ASA (MMX mesalamine, Ipocol, Balsalazide, Pentasa, Olsalazine and 5‐ASA micropellets) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global</b> </p> <p><b>or clinical remission</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>519 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>488 per 1000</b><br/>(446 to 529) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.86 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1968</p> <p>(11 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global or clinical remission was defined as CAI ≤ 4 for patient functional assessment ratings or normal bowel movements and absence of rectal bleeding </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce global or clinical improvement</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/>(267 to 350) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/>(0.77 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1647</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement was defined as improved CAI by ≤ 3 from baseline</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce endoscopic remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to adhere to medication regimen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b><br/>(420 to 511) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/>(0.92 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1576</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included headache, abdominal pain, nausea, flatulence, diarrhea, nasopharyngitis, dyspepsia and vomiting </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1,000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p>(7 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.22 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>677</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events included aggravation of UC and a colonic polyp</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 8 ‐ 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(22 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.57 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1489</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse events leading to withdrawal include abdominal pain, rashes and cephalea</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CAI:</b> clinical activity index; <b>CI:</b> Confidence interval; <b>RR:</b> risk ratio; <b>UC:</b> ulcerative colitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimates come from control arm of meta‐analysis, based on included trials.<br/><sup>b</sup>Downgraded one level due to high risk of bias in two studies in the pooled analysis (both due to lack of blinding).<br/><sup>c</sup>Downgraded one level due to high risk of bias in one study in the pooled analysis (lack of blinding).<br/><sup>d</sup> Downgraded one level due to high risk of bias in one study in the pooled analysis (lack of blinding).<br/><sup>e</sup>Downgraded two levels due to very sparse data (12 events).<br/><sup>f</sup>Downgraded one level due to sparse data (57 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral 5‐ASA versus comparator 5‐ASA for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/full#CD000543-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000543-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐ASA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure to induce global/clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.82, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Dose of 5‐ASA: &lt; 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.82, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Failure to induce global/clinical improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.61, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Dose of 5‐ASA: &lt; 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.64, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.51, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Failure to induce endoscopic remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Dose of 5‐ASA: &lt; 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.56, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Failure to induce endoscopic improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.59, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Dose of 5‐ASA: &lt; 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.82, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.18, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.14, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.10, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.54, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Dose of 5‐ASA: &lt; 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.19, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.65, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Exclusions and withdrawals after study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.51, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Dose of 5‐ASA: &lt; 2 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.42, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Dose of 5‐ASA: 2 ‐ 2.9 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.53, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Dose of 5‐ASA: ≥ 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.41, 0.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐ASA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000543-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐ASA versus sulfasalazine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure to induce global/clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 5‐ASA / SASP &lt; 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.57, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 1/1 &gt; 5‐ASA / SASP ≥ 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 5‐ASA / SASP ≥ 1/1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.59, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Failure to induce global/clinical improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.76, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 5‐ASA / SASP &lt; 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.47, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 1/1 &gt; 5‐ASA / SASP ≥ 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 5‐ASA / SASP ≥ 1/1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Failure to induce endoscopic improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.65, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 5‐ASA / SASP &lt; 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.58, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 1/1 &gt; 5‐ASA / SASP ≥ 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.53, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 5‐ASA / SASP ≥ 1/1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.72, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.36, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 5‐ASA / SASP &lt; 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.10, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 1/1 &gt; 5‐ASA / SASP ≥ 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 5‐ASA / SASP ≥ 1/1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.28, 6.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.24, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 5‐ASA / SASP &lt; 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 1/1 &gt; 5‐ASA / SASP ≥ 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 5‐ASA / SASP ≥ 1/1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.10, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Exclusions and withdrawals after study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.58, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 5‐ASA / SASP &lt; 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 1/1 &gt; 5‐ASA / SASP ≥ 1/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.71, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 5‐ASA / SASP ≥ 1/1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.25, 0.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐ASA versus sulfasalazine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000543-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Once daily dosing versus conventional dosing</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Failure to induce global/clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 MMX once daily (OD) versus twice daily (BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.88, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Salofalk granules once daily (OD) versus three times daily (TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.59, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 MMX once daily (OD) versus Asacol three times daily (TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Pentasa once daily (OD) versus twice daily (BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Mesalazine once daily (OD) versus twice daily (BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Failure to induce global/clinical improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 MMX (OD versus BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 MMX (OD) versus Asacol (TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.55, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Pentasa (OD versus BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.17, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Failure to induce global/clinical improvement (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 MMX (OD versus BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 MMX (OD) versus Asacol (TID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.55, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Failure to induce endoscopic remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Failure to induce endoscopic improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Failure to adhere to medication regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.64, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Compliance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.68, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.54, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Exclusions and withdrawals after study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.74, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Once daily dosing versus conventional dosing</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000543-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐ASA versus comparator 5‐ASA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Failure to induce global/clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 Pentasa comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Failure to induce global/clinical remission (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Failure to induce global/clinical improvement (including remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.74, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Pentasa comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.45, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Failure to induce global/clinical improvement (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.74, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.01, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.22, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.05, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.16, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.57, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.22, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.70, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [0.44, 34.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Exclusions and withdrawals after study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.80, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Asacol comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.67, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Claversal comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.74, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Salofalk comparator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.67, 1.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐ASA versus comparator 5‐ASA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000543-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">5‐ASA dose ranging</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Failure to Induce Global/Clinical Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Salofalk 4.5 g versus 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.96, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Salofalk 4.5 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.69, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Salofalk 3 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.49, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 Pentasa 4 g versus 2.25 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.5 Asacol 3.6 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.61, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.6 MMX mesalazine 4.8 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Failure to Induce Global/Clinical Remission or Improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Asacol 4.8 g versus 1.6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.19, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Asacol 3.6 g versus 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.29, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Asacol 2.4 g versus 1.6 or 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 Asacol 3.6 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.48, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.5 Asacol 4.8 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.6 MMX mesalazine 4.8 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.61, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.7 Pentasa 4 g versus 2.25 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.27, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Development of any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Asacol 4.8 g versus 1.6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.48, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Salofalk 4.5 g versus 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.78, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Salofalk 4.5 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.4 Salofalk 3 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.5 Pentasa 4 g versus 2.25 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 5.3.2 Salofalk 4.5 g versus 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 5.3.5 Pentasa 4 g versus 2.25 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [0.26, 107.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Withdrawal from study due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Asacol 4.8 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.24, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Asacol 4.8 g versus 1.6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.02, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 Asacol 2.4 g versus 1.6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 101.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.4 Salofalk 4.5 g versus 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.50, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.5 Salofalk 4.5 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.34, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.6 Salofalk 3 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.25, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.7 Pentasa 4 g versus 2.25 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Exclusions and withdrawals after entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Salofalk 3 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.38, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Asacol 4.8 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.40, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.3 Asacol 4.8 g versus 1.6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.4 Asacol 3.6 g versus 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.5 Asacol 3.6 g versus 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.09, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.6 Asacol 2.4 g versus 1.6 or 1.2 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.60, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.7 Salofalk 4.5 g versus 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.59, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.8 Salofalk 4.5 g versus 1.5 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.38, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.9 Pentasa 4 g versus 2.25 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">5‐ASA dose ranging</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000543.pub5/references#CD000543-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000543.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000543-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000543-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000543-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000543-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD000543-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD000543-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD000543-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000543-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000543\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000543\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000543\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000543\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000543\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000543.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000543.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000543.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000543.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000543.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725135643"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000543.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725135647"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000543.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e73d518e41be5',t:'MTc0MDcyNTEzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 